Document:

Exhibit
10.6

 

POINT
BIOPHARMA INC.

 

2020 EQUITY INCENTIVE PLAN

 

Section
1.          Purpose.

 

This
plan shall be known as the Point Biopharma Inc. 2020 Equity Incentive Plan (the “Plan”). The purpose of the
Plan is to promote the interests of Point Biopharma Inc., a Delaware corporation (including any successor entity, the “Company”),
its Subsidiaries and its stockholders by (i) attracting and retaining key officers, employees, and directors of, and consultants
to, the Company and its Subsidiaries and Affiliates; (ii) enabling such individuals to participate in the long-term growth and
financial success of the Company; (iii) encouraging ownership of stock in the Company by such individuals; and (iv) linking their
compensation to the long-term interests of the Company and its stockholders.

 

Section
2.         Definitions.

 

As
used in the Plan, the following terms shall have the meanings set forth below:

 

(a)       “Affiliate”
means (i) any entity that, directly or indirectly, is controlled by the Company, (ii) any entity in which the Company has
a significant equity interest, (iii) an affiliate of the Company, as defined in Rule 12b-2 promulgated under Section 12 of the
Exchange Act, and (iv) any entity in which the Company has at least fifty percent (50%) of the combined voting power of the entity’s
outstanding voting securities, in each case as designated by the Board as being a participating employer in the Plan.

 

(b)       “Award”
means any Option, SAR, Restricted Stock, RSU, or other award granted under the Plan to a Participant by the Committee (or
the Board) pursuant to such terms, conditions, restrictions and/or limitations as the Committee (or the Board) may establish or
which are required by applicable legal requirements.

 

(c)       “Award
Agreement” means any written agreement, contract or other instrument or document evidencing any Award.

 

(d)
      “Board” means the Board of Directors of the Company.

 

(e)       “Canadian
Participant” means a Participant that is resident in Canada for purposes of the Income Tax Act (Canada).

 

(f)       “Cause”
shall have the meaning as set forth in the Award Agreement(s). In the case that any Award Agreement does not contain a definition
of “Cause,” it shall mean (i) the Participant’s dishonest statements or acts with respect to the Company or
any Affiliate of the Company, or any current or prospective customers, suppliers vendors or other third parties with which such
entity does business; (ii) the Participant’s commission of (A) a felony or (B) any misdemeanor involving moral turpitude,
deceit, dishonesty or fraud; (iii) the Participant’s failure to perform his assigned duties and responsibilities to the
reasonable satisfaction of the Company which failure continues, in the reasonable judgment of the Company, after written notice
given to the Participant by the Company; (iv) the Participant’s gross negligence, willful misconduct or insubordination
with respect to the Company or any Affiliate of the Company; or (v) the Participant’s material violation of any provision
of any agreement(s) between the Participant and the Company relating to noncompetition, nonsolicitation, nondisclosure and/or
assignment of inventions. With regard to any agreement that defines “Cause” on the occurrence of or in connection
with a Change in Control, such definition of “Cause” shall not apply until a Change in Control actually occurs. A
Termination may also be deemed for Cause if the Company discovers grounds constituting Cause existed prior to the Termination
Date. 

     

     

    

(g)       “Change
in Control” means the consummation of (i) the dissolution or liquidation of the Company, (ii) the sale of all or substantially
all of the assets of the Company on a consolidated basis to an unrelated Person or entity, (iii) a merger, reorganization or consolidation
pursuant to which the holders of the Company’s outstanding voting power immediately prior to such transaction do not own
a majority of the outstanding voting power of the surviving or resulting entity, either directly or indirectly (or its ultimate
parent, if applicable), (iv) the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction
or a series of related transactions by a Person or group of Persons, or (v) any other acquisition of the business of the Company,
as determined by the Board; provided, however, that the Company’s IPO, any subsequent public offering or another
capital raising event, acquisition by an employee benefit plan (or a trust forming a part thereof) maintained by the Company or
any Subsidiary, or a merger effected solely to change the Company’s domicile shall not constitute a Change in Control. Further,
a merger, reorganization or consolidation of the Company does not constitute a “Change in Control” if immediately
after the merger, reorganization or consolidation a majority of the voting power of the capital stock of the continuing or surviving
entity, or any direct or indirect parent corporation of the continuing or surviving entity, will be owned by the Persons who were
the Company’s stockholders immediately prior to the merger or consolidation in substantially the same proportions as their
ownership of the voting power of the Company’s capital stock immediately prior to the merger or consolidation.

 

Unless
otherwise provided in an applicable Award Agreement, solely for the purpose of determining the timing of any payments
pursuant to any Award constituting a “deferral of compensation” subject to Section 409A of the Code, a Change in
Control shall be limited to a “change in the ownership of the Company,” a “change in the effective control
of the Company,” or a “change in the ownership of a substantial portion of the assets of the Company” as
such terms are defined in Section 1.409A-3(i)(5) of the U.S. Treasury Regulations. No Award Agreement shall define a Change
in Control in such a manner that a Change in Control would be deemed to occur prior to the actual consummation of the event
or transaction that results in a change of control of the Company (e.g., upon the announcement, commencement, or stockholder
approval of any event or transaction that, if completed, would result in a change in control of the Company).

 

(h)       “Code”
means the Internal Revenue Code of 1986, as amended from time to time.

 

(i)        “Committee”
means the committee created and appointed by the Board to administer this Plan, or if no committee is created and appointed,
the Board. 

    2

     

    

(j)       “Consultant”
means any natural Person that provides bona fide services to the Company (including a Subsidiary), and such services are not
in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote
or maintain a market for the Company’s securities, and, in the case of a Canadian Participant, (i) provides the services
under a written contract with the Company or a Subsidiary of the Company, and (ii) spends or will spend a significant amount
of time and attention on the affairs and business of the Company or a Subsidiary of the Company. 

 

(k)       “Date
of Grant” or “Grant Date” means the date of grant specified in the Award Agreement, which date shall
be the later of (i) the date on which the Board resolved to grant the Award or (ii) the first day of the Participant’s Service
Relationship.

 

(l)
        “Director” means a member of the Board or a director of a Subsidiary
of the Company.

 

(m)      “Disability”
means, unless otherwise defined in an applicable Award Agreement or other contractual agreement between the Participant and
the Company, a disability as defined in Section 1.409A-3(i)(4) of the Treasury Regulations.

 

(n)       “Employee”
means any individual who is a common-law employee of the Company, a Parent or a Subsidiary.

 

(o)
       “Exchange Act” means the Securities Exchange Act of 1934, as amended
from time to time.

 

(p)       “Exercise
Price” means the purchase price payable to purchase one Share upon the exercise of an Option or the price by which the
value of a SAR shall be determined upon exercise.

 

(q)       “Fair
Market Value” with respect to the Shares, means, for purposes of a grant of an Award as of any date, (i) the closing
sales price of the Shares on the Nasdaq Global Select Market, or any other such exchange or market on which the shares are traded,
on such date, or in the absence of reported sales on such date, the closing sales price on the immediately preceding date on which
sales were reported (or in either case, such other price based on actual trading on the applicable date that the Committee determines
is appropriate) or (ii) in the event there is no public market for the Shares on such date, the fair market value as determined,
in good faith, by the Committee in its sole discretion based on the reasonable application of a reasonable valuation method not
inconsistent with Section 409A of the Code.

 

(r)       “Good
Reason” means, unless otherwise provided in an applicable Award Agreement or other contractual agreement between the
Participant and the Company, (1) a material reduction in Participant’s base salary except for across-the-board salary reductions
similarly affecting all or substantially all similarly situated employees of the Company, or (2) the relocation of the office
at which Participant is to perform the majority of Participant’s duties following a Change in Control to a location more
than fifty (50) miles from the office at which Participant worked immediately prior to the Change in Control. 

    3

     

    

(s)       “Holder”
means, with respect to an Award or any Shares, the Person holding such Award or Shares, including the initial recipient of the
Award or any Permitted Transferee.

 

(t)       “Incentive
Stock Option” or “ISO” means an option to purchase Shares from the Company that meets the requirements
of Section 422 of the Code or any successor provision thereto.

 

(u)       “Initial
Public Offering” or “IPO” means the consummation of the first firm commitment underwritten public
offering pursuant to an effective registration statement under the Securities Act covering the offer and sale by the Company of
its equity securities, as a result of or following which the Stock shall be publicly held.

 

(v)       “Non-Qualified
Stock Option” or “NSO” means an option to purchase Shares from the Company that is not an Incentive
Stock Option.

 

(w)     
“Option” means an Incentive Stock Option or a Non-Qualified Stock Option.

 

(x)       “Parent”
of a specified entity means, any entity that, either directly or indirectly, owns or controls such specified entity, where for
this purpose, “control” means the ownership of stock, securities or other interests that possess at least a majority
of the voting power of such specified entity (including indirect ownership or control of such stock, securities or other interests).

 

(y)       “Participant”
means any Employee, Director, Consultant or other Person who receives an Award under the Plan.

 

(z)       “Permitted
Transferees” shall mean any of the following to whom a Holder may transfer Shares hereunder (as set forth in Section
9): the Holder’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships,
any Person sharing the Holder’s household (other than a tenant or employee), a trust in which these Persons have more than
fifty percent of the beneficial interest, a foundation in which these Persons control the management of assets, and any other
entity in which these Persons own more than fifty percent of the voting interests; provided, however, that any such trust
does not require or permit distribution of any Shares during the term of the Award Agreement unless subject to its terms. Upon
the death of the Holder, the term Permitted Transferees shall also include such deceased Holder’s estate, executors, administrators,
personal representatives, heirs, legatees and distributees, as the case may be. 

 

(aa)    “Person”
means any individual, corporation, partnership, limited liability company, association, joint-stock company, trust, joint
venture, unincorporated organization, government or political subdivision thereof or other entity. 

    4

     

    

(bb)   “Purchase
Price” means the consideration for which one Share may be acquired under the Plan (other than upon exercise of an Option),
as specified by the Board.

 

(cc)    “Restricted
Stock” means any Share granted under Section 5 of the Plan that remain subject to certain vesting conditions and other
restrictions.

 

(dd)    “Restricted
Stock Unit” or “RSU” means an unfunded, unsecured right to receive, on the applicable settlement
date, one Share or an amount in cash or other consideration determined by the Committee to be of equal value as of such settlement
date, subject to certain vesting conditions and other restrictions.

 

(ee)
    “SEC” means the Securities and Exchange Commission or any successor thereto.

 

(ff)      “Section
16” means Section 16 of the Exchange Act and the rules promulgated thereunder and any successor provision thereto as
in effect from time to time.

 

(gg)
    “Securities Act” means the Securities Act of 1933, as amended.

 

(hh)
   “Service Relationship” means any relationship as a full-time employee, part-time employee, director
or other key Person (including Consultants) of the Company, the Parent or any Subsidiary or any successor entity (e.g., a
Service Relationship shall be deemed to continue without interruption in the event an individual’s status changes from
full-time employee to part-time employee or Consultant).

 

(ii)
       “Stock” or “Shares” means the common stock, par value $.001
per share, of the Company.

 

(jj)      “Stock
Appreciation Right” or “SAR” means a stock appreciation right granted under the Plan that entitles
the holder to receive, with respect to each Share encompassed by the exercise of such SAR, the amount determined by the Committee
and specified in an Award Agreement. In the absence of such a determination, the holder shall be entitled to receive, with respect
to each Share encompassed by the exercise of such SAR, the excess of the Fair Market Value on the date of exercise over the Fair
Market Value on the date of grant.

 

(kk)    “Subsidiary”
means any Person (other than the Company) of which a majority of its voting power or its equity securities or equity interest
is owned directly or indirectly by the Company.

 

(ll)      “Ten
Percent Owner” means an employee who owns or is deemed to own (by reason of the attribution rules of Section 424(d)
of the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent of the Company
or any Subsidiary. 

    5

     

    

(mm)
   “Termination” or “Terminated” means that the Participant has for any reason ceased to maintain
a continuous Service Relationship. A Participant will not be deemed to have ceased to maintain a Service Relationship while the
Participant is on a bona fide leave of absence, if such leave was approved by the Company in writing. In the case of an approved
leave of absence, the Committee may make such provisions respecting crediting of service, including suspension of vesting of the
Award (including pursuant to a formal policy adopted from time to time by the Company) it may deem appropriate, except that in
no event may an Option or SAR be exercised after the Expiration Date set forth in the Award Agreement. The Committee will have
sole discretion to determine whether a Participant has Terminated and the effective date on which the Participant ceased to provide
services (the “Termination Date”).

 

(nn)    “Unrestricted
Stock” means any Award granted pursuant to Section 5(b).

 

Section
3.          Eligibility and Administration.

 

(a)       Eligibility.
The Committee will have the authority to select Persons to receive Awards. ISOs may be granted only to Employees. All other types
of Awards may be granted to Employees, Directors, Consultants and other Persons.

 

(b)       Administration
of Plan. The Plan shall be administered by the Board, or at the discretion of the Board, by the Committee, comprised of not
less than two directors. All references herein to the “Committee” shall be deemed to refer to the group then responsible
for administration of the Plan at the relevant time (i.e., either the Board of Directors or a committee or committees of the Board,
as applicable).

 

(c)       Authority
of Committee. The Plan shall be administered by the Committee. Subject to the terms of the Plan and applicable law, and in
addition to other express powers and authorizations conferred on the Committee by the Plan, the Committee shall have full power
and authority in its discretion to:

 

i.         designate
Participants and determine the type or types of Awards to be granted to a Participant;

 

ii.       determine
the number of Shares to be covered by, or with respect to which payments, rights or other matters are to be calculated in connection
with Awards;

 

iii.
       determine the timing, terms, and conditions of any Award;

 

iv.
       accelerate at any time the exercisability or vesting of all or any portion of any Award;

 

v.        determine
whether, to what extent, and under what circumstances Awards may be settled or exercised in cash, Shares, other securities, other
Awards or other property, or canceled, forfeited or suspended and the method or methods by which Awards may be settled, exercised,
canceled, forfeited or suspended; 

    6

     

    

vi.       determine
whether, to what extent, and under what circumstances cash, Shares, other securities, other Awards, other property, and other
amounts payable with respect to an Award shall be deferred either automatically or at the election of the holder thereof or of
the Committee;

 

vii.      interpret
and administer the Plan and any instrument or agreement relating to, or Award made under, the Plan;

 

viii.     subject
to the terms of the Plan (including any restrictions imposed by Section 409A), to extend at any time the period in which an Option
may be exercised;

 

ix.        impose
any limitations on Awards, including limitations on transfers, repurchase provisions and the like, and to exercise repurchase
rights or obligations;

 

x.         except
to the extent prohibited by any provision of the Plan, amend or modify the terms of any Award at or after grant with or without
the consent of the holder of the Award;

 

xi.
        establish, amend, suspend or waive such rules and regulations and appoint such agents as it shall deem appropriate for the administration
of the Plan; and

 

xii.       make
any other determination and take any other action that the Committee deems necessary or desirable for the administration of the
Plan, subject to the exclusive authority of the Board hereunder to amend or terminate the Plan.

 

The
express grant in the Plan of any specific power to the Committee shall not be construed as limiting any power or authority of
the Committee; provided that the Committee may not exercise any right or power reserved to the Board. All designations, determinations,
interpretations, and other decisions under or with respect to the Plan or any Award shall be within the sole discretion of the
Committee, may be made at any time and shall be final, conclusive, and binding upon all Persons, including the Company, any Subsidiary
or Affiliate, any Participant and any holder or beneficiary of any Award.

 

(d)       Action
by the Committee. The exercise of an Option or receipt of an Award shall be effective only if an Award Agreement shall have
been duly executed and delivered on behalf of the Company following the grant of the Option or other Award by the Committee. Subject
to the Charter of the Committee and applicable legal requirements (including the rules and regulations of the Nasdaq Global Select
Market), the Committee may make such rules and regulations for the conduct of its business as it shall deem advisable.

 

(e)       No
Liability. No member of the Board or Committee shall be liable for any action taken or determination made in good faith with
respect to the Plan or any Award granted hereunder.

    7

     

    

Section
4.         Shares Available for Awards.

 

(a)       Shares
Available. Subject to Section 4(b), the number of Shares with respect to which Awards may be granted under the Plan (the
 “Share Reserve”) shall be 1,610,432,1 plus on January 1, 2021 and each January 1 thereafter,
the number of Shares reserved and available for issuance under the Plan shall be automatically adjusted such that the Share
Reserve shall equal 10% of the Company’s fully-diluted shares of Common Stock on such date. 1,610,432 Shares shall be
available for grant as Incentive Stock Options. At all times the Company will reserve and keep available a sufficient number
of Shares as will be required to satisfy the requirements of all Awards granted and outstanding under this Plan. For purposes
of this limitation, the Shares underlying any Awards that are forfeited, canceled, held back upon exercise of an Option or
settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied
without the issuance of Shares or otherwise terminated (other than by exercise) under the Plan shall be added back to the
Share Reserve for issuance under the Plan. The inability of the Company to obtain authority from any regulatory body having
jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any
Shares hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to
which such requisite authority shall not have been obtained.

 

(b)      Adjustments.
In the event that any unusual or non-recurring transactions, including an unusual or non-recurring dividend or other
distribution (whether in the form of an extraordinary cash dividend or a dividend of Shares, other securities or other
property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off,
combination, repurchase or exchange of Shares or other securities of the Company, issuance of warrants or other rights to
purchase Shares or other securities of the Company, or other similar corporate transaction or event affects the Shares, then
the Committee shall in an equitable and proportionate manner (and, as applicable, in such equitable and proportionate manner
as is consistent with Sections 422 and 409A of the Code and the regulations thereunder) either: (i) adjust any or all of (1)
the aggregate number of Shares or other securities of the Company (or number and kind of other securities or property) with
respect to which Awards may be granted under the Plan; (2) the number of Shares or other securities of the Company (or number
and kind of other securities or property) subject to outstanding Awards under the Plan, provided that the number of shares
subject to any Award shall always be a whole number; and (3) the grant or exercise price with respect to any Award under the
Plan; (ii) provide for an equivalent award in respect of securities of the surviving entity of any merger, consolidation or
other transaction or event having a similar effect; or (iii) except in respect of Options held by a Canadian Participant,
make provision for a cash payment to the holder of an outstanding Award.

 

Section
5.         Restricted Stock and Unrestricted Stock.

 

(a)       Awards
of Restricted Stock. The Committee may, in its sole discretion, grant (or sell at par value or such other Purchase Price determined
by the Committee) to an eligible individual an award of Restricted Stock under the Plan. Such Restricted Stock shall be subject
to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions that are not inconsistent
with the Plan and which the Board of Directors deems appropriate for inclusion in an Award Agreement.

 

 

1
Please refer to Exhibit A for a schedule of the initial share reserve and any subsequent increases in the reserve.

    8

     

    

(b)       Awards
of Unrestricted Stock. The Committee may, in its sole discretion, grant (or sell at par value or such other Purchase Price
determined by the Committee) to an eligible individual an award of Unrestricted Stock under the Plan. Unrestricted Stock Awards
may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee.

 

(c)       Vesting
Conditions. The Committee at the time of grant shall specify in the Award Agreement the date or dates and/or the attainment
of pre-established performance goals, objectives and other conditions on which the substantial risk of forfeiture imposed shall
lapse and the Restricted Stock shall become vested and nonforfeitable, subject to such further rights of the Company or its assigns
as may be specified in the Award Agreement.

 

Section
6.         Stock Options and Stock Appreciation Rights.

 

(a)       Award
of Options. The Committee may, in its sole discretion, grant to an eligible individual an award of Options under the Plan.
Each Option granted under this Plan will be evidenced by an Award Agreement which will expressly identify the Option as an ISO
or an NSO, the number of shares subject to the Option, and will be in such form and contain such provisions (which need not be
the same for each Participant) as the Committee may from time to time approve, and which will comply with and be subject to the
terms and conditions of this Plan. In the case of ISOs, the terms and conditions of such grants shall be subject to and comply
with Section 422 of the Code, as from time to time amended, and any regulations implementing such statute. To the extent that
any Option does not qualify as an ISO, it shall be deemed an NSO.

 

(b)       Award
of SARs. The Committee may, in its sole discretion, grant to an eligible individual an award of SARs under the Plan. SARs
may be settled in cash or Shares (which may consist of Restricted Stock or RSUs) having a value equal to the value determined
by multiplying the difference between the Fair Market Value on the date of exercise over the Exercise Price and the number of
Shares with respect to which the SAR is being settled.

 

(c)       Modification,
Extension and Assumption of Options. Within the limitations of the Plan, the Board of Directors may modify, reprice, extend
or assume outstanding Options or may accept the cancellation of outstanding options (whether granted by the Company or another
issuer) in return for the grant of new Options or a different type of award for the same or a different number of Shares and at
the same or a different Exercise Price (if applicable). The foregoing notwithstanding, no modification of an Option shall, without
the consent of the Participant, impair the Participant’s rights or increase the Participant’s obligations under such
Option; provided, however, that a modification of an Option that is otherwise favorable to the Participant (for example, providing
the Participant with additional time to exercise the Option after termination of employment or providing for additional forms
of payment) but causes the Option to lose its tax-favored status (for example, as an ISO) shall not require the consent of the
Participant.

    9

     

    

(d)       Exercise
Price. For all Option and SAR awards, the Committee shall establish the Exercise Price on the Date of Grant, which may not
be less than one hundred percent (100%) of the Fair Market Value of the Shares on the Date of Grant, provided, however, that (i)
this limitation shall not apply to an NSO or SAR granted to a Person who is not a U.S. taxpayer or a Canadian Participant on the
Date of Grant or, except in the case of a Canadian Participant, to an NSO or SAR that is intended either to be exempt from Code
Section 409A as a “short-term deferral” or to comply with the requirements of Code Section 409A and (ii) in the case
of an ISO that is granted to a Ten Percent Owner, the exercise price per share for the Shares covered by such ISO shall not be
less than 110 percent of the Fair Market Value on the Date of Grant.

 

(e)       Term.
Subject to the Committee’s general authority under the Plan, each Option, SAR and all rights and obligations thereunder
shall expire on the date determined by the Committee and specified in the Award Agreement (“Expiration Date”).
The Expiration Date shall not exceed 10 years from the Date of Grant. In the case of an ISO that is granted to a Ten Percent Owner,
the Expiration Date of each Option shall be no more than five years from the Date of Grant.

 

(f)       Exercise.

 

i.        Vesting
and Exercisability. The date(s) upon which an Option or SAR becomes vested and/or exercisable (in installments or otherwise)
shall be determined by the Board in its sole discretion and set forth in the Participant’s Award Agreement. No Option or
SAR shall be exercisable unless the Participant has (i) delivered an executed copy of the applicable Award Agreement to the Company
or (ii) has otherwise agreed to be bound by the terms of the Award Agreement. Options and SARs may only be exercised with respect
to whole Shares only.

 

ii.
        Method of Exercise. An Option or SAR shall be deemed to be exercised when written
notice of such exercise has been received by the Company in accordance with the terms of such Award by the person entitled to
exercise such Award and full payment for the Shares underlying the Award that is exercised has been made.

 

iii.
     Termination of Service Relationship. Any portion of an Option or SAR that is not vested
and exercisable on a Participant’s Termination Date shall immediately expire and be null and void. Once any portion of an
Option or SAR becomes vested and exercisable, the Participant’s right to exercise such portion of the Option or SAR (or
the Participant’s representatives and legatees as applicable) in the event of a Termination shall continue until the earliest
of: (i) the date which is: (A) 12 months following the Termination Date if the Termination is due to death or Disability (or such
longer period of time as determined by the Committee and set forth in the applicable Award Agreement) or (B) three months following
the Termination Date if the Termination is due to any reason other than death, Disability, or Cause (or such longer period of
time as determined by the Committee and set forth in the applicable Award Agreement), or (ii) the Expiration Date set forth in
the Award Agreement. In the event of a Termination for Cause, the Option or SAR will be treated as set forth in Section 12(a).

    10

     

    

Section
7.        Restricted Stock Units.

 

(a)       Awards
of Restricted Stock Units. The Committee may, in its sole discretion, grant to an eligible individual an award of RSUs under
the Plan. Such RSUs shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms
and conditions that are not inconsistent with the Plan and which the Board of Directors deems appropriate for inclusion in an
Award Agreement. No RSU will have a term longer than ten (10) years from the Date of Grant.

 

(b)       Vesting
Conditions. Each RSU Award Agreement shall specify the vesting requirements applicable to the RSUs subject thereto, which
the Board of Directors shall determine in its sole discretion. On or promptly following the vesting date or dates applicable to
any RSU, but in no event later than March 15 of the year following the year in which such vesting occurs, such RSU(s) shall be
settled in the form of cash or Shares, as specified in the Award Agreement. RSUs may not be sold, assigned, transferred, pledged,
or otherwise encumbered or disposed of. To the extent permissible under applicable law, the Committee may permit a Participant
to defer payment under a RSU to a date or dates after the RSU is earned, provided that the terms of the RSU and any deferral satisfy
the requirements of Section 409A of the Code (or any successor) and any regulations or rulings promulgated thereunder.

 

(c)       Forfeiture.
Unless an Award Agreement provides otherwise, upon termination of the Participant’s Service Relationship and upon such other
times specified in the Award Agreement, any unvested RSUs shall be forfeited to the Company.

 

(d)       Death
of Recipient. Any RSUs that become distributable after a Participant’s death shall be distributed to the
Participant’s estate or to any Person who has acquired such RSUs directly from the recipient by beneficiary
designation, bequest or inheritance.

 

(e)       Creditors’
Rights. A holder of RSUs shall have no rights other than those of a general creditor of the Company. RSUs represent an unfunded
and unsecured obligation of the Company, subject to the terms and conditions of the applicable Award Agreement.

 

Section
8.        Payment for Awards.

 

(a)       General
Rule. The entire Purchase Price or Exercise Price of Shares issued under the Plan shall be payable in cash or cash equivalents
at the time when such Shares are purchased. In addition, the Board in its sole discretion may also permit payment through any
of the methods (or combination of methods) described in (b) through (g) below.

 

(b)       Services
Rendered. Shares may be awarded under the Plan in consideration of past or future services rendered to the Company, a Parent
or a Subsidiary prior to the award.

    11

     

    

(c)       Promissory
Note. All or a portion of the Purchase Price or Exercise Price (as the case may be) of Shares issued under the Plan may be
paid with a promissory note. The Shares shall be pledged as security for payment of the principal amount of the promissory note
and interest thereon. The interest rate payable under the terms of the promissory note shall not be less than the minimum rate
(if any) required to avoid the imputation of additional interest under the Code. Subject to the foregoing, the Board in its sole
discretion shall specify the term, interest rate, recourse, amortization requirements (if any) and other provisions of such note.
The portion of the Exercise Price or Purchase Price, as the case may be, equal to the par value (if any) of the Shares must be
paid in cash or other legal consideration permitted by the laws under which the Company is then incorporated or organized

 

(d)       Surrender
of Stock. If permitted by the Committee and the Initial Public Offering has occurred (or the Stock otherwise becomes publicly-traded),
through the delivery (or attestation to the ownership) of Shares that have been purchased by the Participant on the open market
or that are beneficially owned by the Participant and are not then subject to restrictions under any Company plan. To the extent
required to avoid variable accounting treatment under ASC 718 or other applicable accounting rules, such surrendered Shares if
originally purchased from the Company shall have been owned by the Participant for at least six months. Such surrendered Shares
shall be valued at Fair Market Value on the exercise date.

 

(e)       Cashless
Exercise. All or part of the Exercise Price and any withholding taxes may be paid pursuant to a cashless exercise arrangement
implemented by the Committee in connection with the Plan.

 

(f)       Net
Exercise. An Option may permit exercise through a “net exercise” arrangement, whereby the Company will reduce
the number of Shares issuable upon exercise by the largest whole number of Shares with a Fair Market Value that does not exceed
the aggregate exercise price, but only with respect to Options that are not ISOs.

 

(g)       Other
Forms of Payment. To the extent that an Award Agreement so provides, the Purchase Price or Exercise Price of Shares issued
under the Plan may be paid in any other form permitted by the Delaware General Corporation Law, as amended.

 

Payment
instruments will be received subject to collection. No certificates for Shares so purchased will be issued to the Participant
or, with respect to uncertificated Stock, no transfer to the Participant on the records of the Company will take place, until
the Company has completed all steps it has deemed necessary to satisfy legal requirements relating to the issuance and sale of
the Shares, which steps may include, without limitation, (i) receipt of a representation from the Participant at the time of exercise
of the Option that the Participant is purchasing the Shares for the Participant’s own account and not with a view to any
sale or distribution of the Shares or other representations relating to compliance with applicable law governing the issuance
of securities, (ii) the legending of the certificate (or notation on any book entry) representing the Shares to evidence the foregoing
restrictions, and (iii) obtaining from the Participant payment or provision for all withholding taxes due as a result of the exercise
of the Option. The delivery of certificates representing the shares of Stock (or the transfer to the Participant on the records
of the Company with respect to uncertificated Stock) to be purchased pursuant to the exercise of a Stock Option will be contingent
upon (A) receipt from the Participant (or a purchaser acting in his or her stead in accordance with the provisions of the Option)
by the Company of the full Purchase Price for such Shares and the fulfillment of any other requirements contained in the Award
Agreement or applicable provisions of laws and (B) if required by the Company, the Participant shall have entered into any stockholders
agreements or other agreements with the Company and/or certain other of the Company’s stockholders relating to the Stock.
In the event the Participant chooses to pay the Purchase Price by previously-owned Shares through the attestation method, the
number of Shares transferred to the Participant upon the exercise of the Option shall be net of the number of Shares attested
to.

    12

     

    

Section
9.        Transfer Restrictions; Right of First Refusal; Repurchase Rights.

 

(a)       Restrictions
on Transfer of Awards. An Award shall be transferable by the Participant only by (i) a beneficiary designation, (ii) a will
or (iii) the laws of descent and distribution, except as may be provided otherwise by the Board. If the Board so provides, in
an Award Agreement or otherwise, an NSO may be transferable to the extent permitted by Rule 701 under the Securities Act (“Rule
701”), provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions
of this Plan and the applicable Award Agreement, including the execution of a stock power upon the issuance of Shares. An ISO
may be exercised during the lifetime of the Participant only by the Participant or by the Participant’s guardian or legal
representative.

 

(b)       Shares.
No Shares shall be sold, assigned, transferred, pledged, hypothecated, given away or in any other manner disposed of or encumbered,
whether voluntarily or by operation of law, unless (i) agreed upon in writing by the Committee, (ii) the transfer is in compliance
with the terms of the applicable Award Agreement, all applicable securities laws (including, without limitation, the Securities
Act), and with the terms and conditions of this Section, (iii) the transfer does not cause the Company to become subject to the
reporting requirements of the Exchange Act, and (iv) the transferee consents in writing to be bound by the provisions of the Plan
and the Award Agreement, including this Section. In connection with any proposed transfer, the Committee may require the transferor
to provide at the transferor’s own expense an opinion of counsel to the transferor, satisfactory to the Committee, that
such transfer is in compliance with all foreign, federal and state securities laws (including, without limitation, the Securities
Act). Any attempted transfer of Shares not in accordance with the terms and conditions of this Section shall be null and void,
and the Company shall not reflect on its records any change in record ownership of any Shares as a result of any such transfer,
shall otherwise refuse to recognize any such transfer and shall not in any way give effect to any such transfer of Shares. The
Company shall be entitled to seek protective orders, injunctive relief and other remedies available at law or in equity including,
without limitation, seeking specific performance or the rescission of any transfer not made in strict compliance with the provisions
of this Section. Subject to the foregoing general provisions, and unless otherwise provided in the applicable Award Agreement,
Shares may be transferred pursuant to the following specific terms and conditions (provided that with respect to any transfer
of Restricted Stock, all vesting and forfeiture provisions shall continue to apply with respect to the original recipient).

 

i.        Transfers
to Permitted Transferees. Subject to the requirements of this Section (including Company approval), the Holder may transfer
any or all of the Shares to one or more Permitted Transferees; provided, however, that following such transfer, such Shares shall
continue to be subject to the terms of this Plan (including this Section) and such Permitted Transferee(s) shall, as a condition
to any such transfer, deliver a written acknowledgment to that effect to the Company and shall deliver a stock power to the Company
with respect to the Shares. Notwithstanding the foregoing, the Holder may not transfer any of the Shares to a Person whom the
Company reasonably determines is a direct competitor or a potential competitor of the Company or any of its Subsidiaries. 

    13

     

    

ii.       Transfers
Upon Death. Upon the death of the Holder, any Shares then held by the Holder at the time of such death and any Shares
acquired after the Holder’s death by the Holder’s legal representative shall be subject to the provisions of this
Plan, and the Holder’s estate, executors, administrators, personal representatives, heirs, legatees and distributees
shall be obligated to convey such Shares to the Company or its assigns under the terms contemplated by the Plan and the Award
Agreement.

 

(c)       Right
of First Refusal. In the event that a Holder desires at any time to sell or otherwise transfer all or any part of his or
her Shares (other than shares of Restricted Stock which by their terms are not transferrable), the Holder first shall give
written notice to the Company of the Holder’s intention to make such transfer. Such notice shall state the number of
Shares that the Holder proposes to sell (the “Offered Shares”), the price and the terms at which the
proposed sale is to be made and the name and address of the proposed transferee. At any time within 30 days after the receipt
of such notice by the Company, the Company or its assigns may elect to purchase all or any portion of the Offered Shares at
the price and on the terms offered by the proposed transferee and specified in the notice. The Company or its assigns shall
exercise this right by mailing or delivering written notice to the Holder within the foregoing 30-day period. If the Company
or its assigns elect to exercise its purchase rights, the closing for such purchase shall, in any event, take place within 45
days after the receipt by the Company of the initial notice from the Holder. In the event that the Company or its assigns do
not elect to exercise such purchase right, or in the event that the Company or its assigns do not pay the full purchase price
within such 45-day period, the Holder shall be required to pay a transaction processing fee of $10,000 to the Company (unless
waived by the Committee) and then may, within 60 days thereafter, sell the Offered Shares to the proposed transferee and at
the same price and on the same terms as specified in the Holder’s notice. Any Shares not sold to the proposed
transferee shall remain subject to the Plan. If the Holder is a party to any stockholders agreements or other agreements with
the Company and/or certain other of the Company’s stockholders relating to the Shares, (i) the transferring Holder
shall comply with the requirements of such stockholders agreements or other agreements relating to any proposed transfer of
the Offered Shares, and (ii) any proposed transferee that purchases Offered Shares shall enter into such stockholders
agreements or other agreements with the Company and/or certain of the Company’s stockholders relating to the Offered
Shares on the same terms and in the same capacity as the transferring Holder.

 

(d)       Company’s
Right of Repurchase.

 

i.        Right
of Repurchase for Unvested Shares Issued Upon the Exercise of an Option. Upon a Termination, the Company or its assigns shall
have the right and option to repurchase from a Holder of Shares acquired upon exercise of an Option which are still subject to
a risk of forfeiture as of the Termination. Such repurchase rights may be exercised by the Company within the later of (A) six
months following the date of such Termination or (B) seven months after the acquisition of Shares upon exercise of an Option.
The repurchase price shall be equal to the lower of the original per share price paid by the Holder, subject to adjustment as
provided in Section 4(b) of the Plan, or the current Fair Market Value of such Shares as of the date the Company elects to exercise
its repurchase rights.

    14

     

    

ii.     
   Right of Repurchase and Forfeiture With Respect to Restricted Stock.

 

 (1)       Upon
a Termination, the Company or its assigns shall have the right and option to repurchase from a Holder of Shares received pursuant
to a Restricted Stock Award any Shares that are still subject to a risk of forfeiture as of the Termination. Such repurchase right
may be exercised by the Company within six months following the date of such Termination. The repurchase price shall be the lower
of the original per share Purchase Price paid by the Holder, subject to adjustment as provided in Section 4(b) of the Plan, or
the current Fair Market Value of such Shares as of the date the Company elects to exercise its repurchase rights.

 

 (2)       If
a Restricted Stock Award is issued in consideration of services rendered, a Holder shall no longer have any rights as a holder
of Restricted Stock and shall be deemed to have been forfeited all such unvested Shares upon a Termination (“Automatic
Forfeiture”).

 

iii.
       Procedure. Any repurchase right of the Company shall be exercised by the Company
or its assigns by giving the Holder notice on or before the last day of the repurchase period of its intention to exercise
such repurchase right. Upon such notification, the Holder shall promptly surrender to the Company, free and clear of any
liens or encumbrances, any certificates representing the Shares being purchased, together with a duly executed stock power
for the transfer of such Shares to the Company or the Company’s assignee or assignees. Upon the Company’s or its
assignee’s receipt of the certificates from the Holder, the Company or its assignee or assignees shall deliver to him,
her or them a check for the applicable repurchase price; provided, however, that the Company may pay the repurchase price by
offsetting and canceling any indebtedness then owed by the Holder to the Company. An Automatic Forfeiture shall require no
action by the Company or its assigns.

 

(e)       Reserved.

 

(f)
       Escrow Arrangement.

 

i.        Escrow.
In order to carry out the provisions of this Section of this Plan more effectively, the Company shall hold any Shares issued pursuant
to Awards granted under the Plan in escrow together with separate stock powers executed by the Holder in blank for transfer. The
Company shall not dispose of the Shares except as otherwise provided in this Plan. In the event of any repurchase by the Company
(or any of its assigns), the Company is hereby authorized by the Holder, as the Holder’s attorney-in-fact, to date and complete
the stock powers necessary for the transfer of the Shares being purchased and to transfer such Shares in accordance with the terms
hereof. At such time as any Shares are no longer subject to the Company’s repurchase and first refusal rights, the Company
shall, at the written request of the Holder, deliver to the Holder a certificate representing such Shares with the balance of
the Shares to be held in escrow pursuant to this Section.

    15

     

    

ii.       Remedy.
Without limitation of any other provision of this Plan or other rights, in the event that a Holder or any other Person is
required to sell a Holder’s Shares pursuant to the provisions of Sections 9(c) or (d) hereof and in the further event
that he or she refuses or for any reason fails to deliver to the Company or its designated purchaser of such Shares the
certificate or certificates evidencing such Shares together with a related stock power, the Company or such designated
purchaser may deposit the applicable Purchase Price for such Shares with a bank designated by the Company, or with the
Company’s independent public accounting firm, as agent or trustee, or in escrow, for such Holder or other Person, to be
held by such bank or accounting firm for the benefit of and for delivery to him, her, them or it, and/or, in its discretion,
pay such Purchase Price by offsetting any indebtedness then owed by such Holder as provided above. Upon any such deposit
and/or offset by the Company or its designated purchaser of such amount and upon notice to the Person who was required to
sell the Shares to be sold pursuant to the provisions of Sections 9(c) or (d), such Shares shall at such time be deemed to
have been sold, assigned, transferred and conveyed to such purchaser, such Holder shall have no further rights thereto (other
than the right to withdraw the payment thereof held in escrow, if applicable), and the Company shall record such transfer in
its stock transfer book or in any appropriate manner.

 

(g)       Lockup
Provision. If requested by the Company, a Holder shall not sell or otherwise transfer or dispose of any Shares (including,
without limitation, pursuant to Rule 144 under the Securities Act) held by him or her for such period following the effective
date of a public offering by the Company of Shares as the Company shall specify reasonably and in good faith. If requested by
the underwriter engaged by the Company, each Holder shall execute a separate letter confirming his or her agreement to comply
with this Section.

 

(h)       Adjustments
for Changes in Capital Structure. If, as a result of any reorganization, recapitalization, reclassification, stock dividend,
stock split, reverse stock split or other similar change in the Common Stock, the outstanding Shares are increased or decreased
or are exchanged for a different number or kind of securities of the Company, the restrictions contained in this Section shall
apply with equal force to additional and/or substitute securities, if any, received by Holder in exchange for, or by virtue of
his or her ownership of, Shares.

 

(i)       Termination.
The terms and provisions of Section 9(c) and Section 9(d) (except for the Company’s right to repurchase or receive forfeiture
of Shares still subject to a risk of forfeiture upon a Termination) shall terminate upon the closing of the Company’s Initial
Public Offering or upon consummation of any Change in Control, in either case as a result of which Shares are registered under
Section 12 of the Exchange Act and publicly-traded on any national security exchange.

    16

     

    

Section
10.       Change in Control.

 

In
the event that the Company is subject to a Change in Control, all Options and SARs with time-based vesting conditions or restrictions
that are not vested and/or exercisable immediately prior to the effective time of the Change in Control shall become fully vested
and exercisable as of the effective time of the Change in Control, all other Awards with time-based vesting, conditions or restrictions
shall become fully vested and nonforfeitable as of the effective time of the Change in Control, and all Awards with conditions
and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a Change
in Control in the Administrator’s discretion or to the extent specified in the relevant Award Agreement.

 

In
the event the Company is subject to a Change in Control, the Company shall have the right, but not the obligation, to make or
provide for a payment to a Participant, without any consent of the Participant, in exchange for the cancellation of an Award in
an amount determined by the Committee, with such determination having final and binding effect on all parties. Such payment shall
be made in the form of cash, cash equivalents, or securities of the surviving corporation or its parent. In addition, any escrow,
indemnification, holdback, earn-out or similar provisions in the transaction agreement may apply to such payment to the same extent
and in the same manner as such provisions apply to the holders of Stock. Receipt of the payment described in this subsection may
be conditioned upon the Participant acknowledging such escrow, indemnification, holdback, earn-out or other provisions on a form
prescribed by the Company. Notwithstanding the forgoing, in the case of an Option or SAR with an exercise price equal to or greater
than the per share sale price in a Change in Control, such Option or SAR shall be cancelled for no consideration.

 

Section
11.       Amendment and Termination.

 

(a)       Amendments
to the Plan. The Board may amend, alter, suspend, discontinue or terminate the Plan or any portion thereof at any time (and
in accordance with Section 409A of the Code with regard to Awards subject thereto); provided that no such amendment, alteration,
suspension, discontinuation or termination shall be made without stockholder approval if such approval is necessary to comply
with any tax or regulatory requirement (including the rules and regulations of the principal securities market or exchange on
which the Shares are traded) for which or with which the Board deems it necessary or desirable to comply.

 

(b)       Amendments
to Awards. Subject to the terms of the Plan, the Committee may waive any conditions or rights under, amend any terms of or
alter, suspend, discontinue, cancel or terminate, any Award theretofore granted, prospectively or retroactively (and in accordance
with Section 409A of the Code with regard to Awards subject thereto); provided that any such waiver, amendment, alteration, suspension,
discontinuance, cancellation or termination that would materially and adversely affect the rights of any Participant or any holder
or beneficiary of any Award theretofore granted shall not to that extent be effective without the consent of the affected Participant,
holder or beneficiary.

    17

     

    

(c)       Recoupment
of Awards. Any Award granted pursuant to this Plan shall be subject to mandatory repayment by the Participant to the Company
(i) to the extent set forth in any Award Agreement, (ii) to the extent that such Participant is, or in the future becomes, subject
to (a) any “clawback” or recoupment policy adopted by the Company or any Affiliate thereof to comply with the requirements
of any applicable laws, rules or regulations, including pursuant to final rules adopted by the SEC pursuant to the Dodd-Frank
Wall Street Reform and Consumer Protection Act, or otherwise, or (b) any applicable laws which impose mandatory recoupment, under
circumstances set forth in such applicable laws, including the Sarbanes-Oxley Act of 2002.

 

Section
12.       General Provisions.

 

(a)       Termination
for Cause. Unless otherwise determined by the Committee, if a Participant is Terminated for Cause, any outstanding Awards
held by such Participant (whether vested or unvested) shall terminate immediately upon the Termination Date. However, an Award
Agreement may provide that upon Termination of a Participant for Cause, only unvested and outstanding Awards shall terminate immediately
upon the Termination Date. For purposes hereof, the Committee’s determination of the reason for Termination shall be conclusive
and binding on the Participant and his or her representatives, legatees and any Permitted Transferee.

 

(b)       Delivery
of Stock Certificates. Stock certificates to grantees under the Plan shall be deemed delivered for all purposes when the Company
or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee,
at the grantee’s last known address on file with the Company; provided that stock certificates to be held in escrow pursuant
to Section 9 of the Plan shall be deemed delivered when the Company shall have recorded the issuance in its records. Uncertificated
Stock shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have given to
the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee’s
last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic
 “book entry” records).

 

(c)       Dividend
Equivalents. Subject to the terms of the Plan, no dividends, dividend equivalent rights or other distributions shall be granted
with respect to Options or SARs, but in the sole and complete discretion of the Committee, any other Award may provide the Participant
with dividends, dividend equivalents or other distributions, payable in cash, Shares, other securities or other property on a
current or deferred basis. Any such rights (which the Company is under no duty to declare) will be set forth in an Award Agreement
or other agreement entered into between the Company and the Participant.

    18

     

    

(d)       Compliance
with Section 409A of the Code. No Award (or modification thereof) shall provide for deferral of compensation that does
not comply with Section 409A of the Code unless the Committee, at the time of grant, specifically provides that the Award is
not intended to comply with Section 409A of the Code. Notwithstanding any provision of this Plan to the contrary, if one or
more of the payments or benefits received or to be received by a Participant pursuant to an Award would cause the Participant
to incur any additional tax or interest under Section 409A of the Code, the Committee may reform such provision to maintain
to the maximum extent practicable the original intent of the applicable provision without violating the provisions of section
409A of the Code. In the event that it is reasonably determined by the Board or Committee that, as a result of Section 409A
of the Code, payments in respect of any Award under the Plan may not be made at the time contemplated by the terms of the
Plan or the relevant Award agreement, as the case may be, without causing the Participant holding such Award to be subject to
taxation under Section 409A of the Code, the Company will make such payment on the first day that would not result in the
Participant incurring any tax liability under Section 409A of the Code; which, if the Participant is a “specified
employee” within the meaning of the Section 409A, shall be the first day following the six-month period beginning on
the date of Participant’s termination of employment. Unless otherwise provided in an Award Agreement or other document
governing the issuance of such Award, payment of any Performance Award intended to qualify as a “short term
deferral” within the meaning of Section 1.409A-1(b)(4)(i) of the U.S. Treasury Regulations shall be made between the
first day following the close of the applicable Performance Period and the last day of the “applicable 2 1⁄2 month
period” as defined therein. Notwithstanding the foregoing, each Participant is solely responsible and liable for the
satisfaction of all taxes and penalties that may be imposed on him or her, or in respect of any payment or benefit delivered
in connection with the Plan (including any taxes and penalties under Section 409A of the Code), and the Company shall not
have any obligation to indemnify or otherwise hold any Participant harmless from any of such taxes or penalties.

 

(e)       No
Rights to Awards; Reservation of Rights. No Person shall have any claim to be granted any Award, and there is no obligation
for uniformity of treatment of Participants or holders or beneficiaries of Awards. The terms and conditions of Awards need not
be the same with respect to each Participant. The grant of an Award pursuant to the Plan shall not affect in any way the right
or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure,
to merge or consolidate or to dissolve, liquidate, sell or transfer all or any part of its business or assets. Participation in
the Plan and receipt of Awards by Participants is voluntary.

 

(f)       Share
Certificates. All certificates for Shares or other securities of the Company or any Subsidiary or Affiliate delivered under
the Plan pursuant to any Award or the exercise thereof shall be subject to such stop transfer orders and other restrictions as
the Committee may deem advisable under the Plan or the rules, regulations and other requirements of the SEC or any state securities
commission or regulatory authority, any stock exchange or other market upon which such Shares or other securities are then listed,
and any applicable Federal or state laws, and the Committee may cause a legend or legends to be put on any such certificates to
make appropriate reference to such restrictions.

    19

     

    

(g)       Withholding.
A Participant shall, no later than the date as of which the value of an Award or of any Shares or other amounts received
thereunder first becomes includable in the gross income of the Participant for income tax purposes, pay to the Company, or
make arrangements satisfactory to the Committee regarding payment of, any Federal, state, provincial or local taxes of any
kind required by law to be withheld by the Company with respect to such income. The Company and any Subsidiary shall, to the
extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the
Participant. The Company’s obligation to deliver stock certificates (or evidence of book entry) to any Participant is
subject to and conditioned on any such tax withholding obligations being satisfied by the Participant. Without limiting the
generality of the foregoing, the Committee may in its discretion permit a Participant to satisfy or arrange to satisfy, in
whole or in part, the tax obligations incident to an Award by: (i) electing to have the Company withhold Shares or other
property otherwise deliverable to such Participant pursuant to the Award (provided, however, that the amount of any Shares so
withheld shall not exceed the amount necessary to satisfy required federal, state local and foreign withholding obligations
using the maximum or other applicable statutory withholding rates for federal, state, local and/or foreign tax purposes,
including payroll taxes, that are applicable to supplemental taxable income) and/or (ii) having the Company cause its
transfer agent to sell, on behalf of the Participant, a number of Shares with an aggregate Fair Market Value (as of the date
the withholding is effected) that would satisfy the withholding amount due and remitting the proceeds from such sale to the
Company.

 

(h)       Award
Agreements. Each Award hereunder shall be evidenced by an Award Agreement that shall be delivered to the Participant and
may specify the terms and conditions of the Award and any rules applicable thereto. The provisions of the various Award
Agreements (including, for the avoidance of doubt, Awards of the same type) need not be identical. Unless otherwise
determined by the Committee, an Award shall expire if the recipient has not executed an Award Agreement within 45 days after
such right was communicated to the Person by the Company. In the event of a conflict between the terms of the Plan and any
Award Agreement, the terms of the Plan shall prevail. The Committee or, except to the extent prohibited under applicable law,
its delegate(s) may establish the terms of agreements or other documents evidencing Awards under this Plan and may, but need
not, require as a condition to any such agreement’s or document’s effectiveness that such agreement or document
be executed by the Participant, including by electronic signature or other electronic indication of acceptance, and that such
Participant agree to such further terms and conditions as specified in such agreement or document. The grant of an Award
under this Plan shall not confer any rights upon the Participant holding such Award other than such terms, and subject to
such conditions, as are specified in this Plan as being applicable to such type of Award (or to all Awards) or as are
expressly set forth in the agreement or other document evidencing such Award.

 

(i)       No
Limit on Other Compensation Arrangements. Nothing contained in the Plan shall prevent the Company or any Subsidiary or Affiliate
from adopting or continuing in effect other compensation arrangements, which may, but need not, provide for the grant of Options,
SARs, Restricted Stock, Restricted Stock Units or other types of Awards provided for hereunder.

 

(j)       No
Right to Employment or Other Relationship. This Plan, any Award Agreement, and the grant of an Award shall not be construed
as giving a Participant the right to be retained in the employ or other Relationship of the Company or any Subsidiary or Affiliate.
Further, the Company or a Subsidiary or Affiliate may at any time Terminate a Participant from employment, free from any liability
or any claim under the Plan, unless otherwise expressly provided in an Award Agreement.

    20

     

    

(k)       No
Rights as Stockholder. Subject to the provisions of the Plan and the applicable Award Agreement, no Participant or Holder
of any Award shall have any rights as a stockholder with respect to any Shares (including voting rights) to be distributed under
the Plan until such Person been issued such Shares subject to the Award and such Shares are not subject to any forfeiture or vesting
conditions.

 

(l)       Data
Privacy. As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the
collection, use and transfer, in electronic or other form, of personal data as described in this subsection by and among the
Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant’s
participation in the Plan. The Company and its Subsidiaries and affiliates may hold certain personal information about a
Participant, including the Participant’s name, address and telephone number; birthdate; social security, insurance
number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries
and affiliates; and Award details, to implement, manage and administer the Plan and Awards (the “Data”).
The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement,
administer and manage a Participant’s participation in the Plan, and the Company and its Subsidiaries and affiliates
may transfer the Data to third parties assisting the Company with Plan implementation, administration and management. These
recipients may be located in the Participant’s country, or elsewhere, and the Participant’s country may have
different data privacy laws and protections than the recipients’ country. By accepting an Award, each Participant
authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, to implement,
administer and manage the Participant’s participation in the Plan, including any required Data transfer to a broker or
other third party with whom the Company or the Participant may elect to deposit any Shares. The Data related to a Participant
will be held only as long as necessary to implement, administer, and manage the Participant’s participation in the
Plan. A Participant may, at any time, view the Data that the Company holds regarding such Participant, request
additional information about the storage and processing of the Data regarding such Participant, recommend any necessary
corrections to the Data regarding the Participant or refuse or withdraw the consents in this subsection in writing, without
cost, by contacting the local human resources representative. The Company may cancel Participant’s ability to
participate in the Plan and, in the Committee’s discretion, the Participant may forfeit any outstanding Awards if the
Participant refuses or withdraws the consents in this subsection. For more information on the consequences of refusing or
withdrawing consent, Participants may contact their local human resources representative.

 

(m)       Governing
Law. The validity, construction and effect of the Plan and any rules and regulations relating to the Plan, an Award and any
Award Agreement shall be determined in accordance with the laws of the State of Delaware without giving effect to conflicts of
laws principles.

 

(n)       Severability.
If any provision of the Plan or any Award is, or becomes, or is deemed to be invalid, illegal or unenforceable in any jurisdiction
or as to any Person or Award, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such
provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be construed or deemed amended
without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall
be stricken as to such jurisdiction, Person or Award and the remainder of the Plan and any such Award shall remain in full force
and effect.

    21

     

    

(o)       Other
Laws. Although this Plan is intended to be a written compensatory benefit plan within the meaning of Rule 701, grants may
be made pursuant to this Plan that do not qualify for exemption under Rule 701. The Committee may refuse to allow exercise of
an Award or issue or transfer any Shares or other consideration under an Award if, acting in its sole discretion, it determines
that the issuance or transfer of such Shares or such other consideration might violate any applicable law or regulation (including
applicable non-U.S. laws or regulations) or entitle the Company to recover the same under Exchange Act Section 16(b), and any
payment tendered to the Company by a Participant, other holder or beneficiary in connection with the exercise of such Award shall
be promptly refunded to the relevant Participant, holder or beneficiary.

 

(p)       No
Trust or Fund Created. Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any
kind or a fiduciary relationship between the Company or any Subsidiary or Affiliate and a Participant or any other Person. To
the extent that any Person acquires a right to receive payments from the Company or any Subsidiary or Affiliate pursuant to an
Award, such right shall be no greater than the right of any unsecured general creditor of the Company or any Subsidiary or Affiliate.
Any amounts payable to Participant pursuant to the Plan shall be unfunded and unsecured obligations for all purposes, including,
without limitation, Title I of the Employee Retirement Income Security Act of 1974, as amended.

 

(q)       No
Fractional Shares. No fractional Shares shall be issued or delivered pursuant to the Plan or any Award, and the Committee
shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any fractional Shares
or whether such fractional Shares or any rights thereto shall be canceled, terminated or otherwise eliminated. In the case of
Options held by a Canadian Participant, in the event that the number of Shares issuable to such Participant on the exercise of
such Options would otherwise include a fractional Share, such number of Shares shall be rounded down to the nearest whole number
of Shares and no amount shall be payable to such Participant in respect of such fractional Share.

 

(r)       No
Effect on Retirement and Other Benefit Plans. Except as specifically provided in a retirement or other benefit plan of
the Company, Subsidiary or Parent, Awards shall not be deemed compensation for purposes of computing benefits or
contributions under any retirement plan, and shall not affect any benefits under any other benefit plan of any kind or any
benefit plan subsequently instituted under which the availability or amount of benefits is related to level of compensation.
The Plan is not a “Pension Plan” or “Welfare Plan” under the Employee Retirement Income Security Act
of 1974, as amended. Neither the adoption of the Plan by the Board, the submission of the Plan to the stockholders of the
Company for approval, nor any provision of the Plan will be construed as creating any limitations on the power of the Board
to adopt such additional compensation arrangements as it may deem desirable, including, without limitation, the granting of
Awards otherwise than under the Plan, and such arrangements may be either generally applicable or applicable only in specific
cases.

    22

     

    

(s)       Headings.
Headings are given to the sections and subsections of the Plan solely as a convenience to facilitate reference. Such headings
shall not be deemed in any way material or relevant to the construction or interpretation of the Plan or any provision thereof.

 

(t)       Trading
Policy Restrictions. Option exercises and other Awards under the Plan shall be subject to the Company’s insider
trading policy-related restrictions, terms and conditions as may be established by the Committee, or in accordance with
policies set by the Committee, from time to time.

 

(u)       Designation
of Beneficiary. Each Participant to whom an Award has been made under the Plan may designate a beneficiary or
beneficiaries to exercise any Award on or after the Participant’s death or receive any payment under any Award payable
on or after the Participant’s death. Any such designation shall be on a form provided for that purpose by the Committee
and shall not be effective until received by the Committee. If no beneficiary has been designated by a deceased Participant,
or if the designated beneficiaries have predeceased the Participant, the beneficiary shall be the Participant’s
estate.

 

(v)       Legend.
Any certificate(s) representing the Shares shall carry substantially the following legend (and with respect to uncertificated
Stock, the book entries evidencing such shares shall contain the following notation):

 

The
transferability of this certificate and the shares of stock represented hereby are subject to the restrictions, terms and conditions
(including repurchase and restrictions against transfers) contained in the Point Biopharma Inc. 2020 Equity Incentive Plan and
any agreements entered into thereunder by and between the company and the holder of this certificate (a copy of which is available
at the offices of the company for examination).

 

(w)       Information
to Holders of Options. In the event the Company is relying on the exemption from the registration requirements of Section
12(g) of the Exchange Act contained in paragraph (f)(1) of Rule 12h-1 of the Exchange Act, the Company shall provide the information
described in Rule 701(e)(3), (4) and (5) of the Securities Act to all holders of Options in accordance with the requirements thereunder.
The foregoing notwithstanding, the Company shall not be required to provide such information unless the optionholder has agreed
in writing, on a form prescribed by the Company, to keep such information confidential.

    23

     

    

Section
13.        Term of the Plan.

 

(a)       Effective
Date. The Plan will become effective on the date that it is adopted by the Board (the “Effective
Date”). This Plan will be approved by the stockholders of the Company (excluding Shares issued pursuant to this
Plan), consistent with applicable laws, within twelve (12) months before or after the Effective Date. Upon the Effective
Date, the Board may grant Awards pursuant to this Plan, provided, however, that: (A) no Option or SAR may be exercised prior
to initial stockholder approval of this Plan and (B) no Option or SAR granted pursuant to an increase in the number of Shares
approved by the Board shall be exercised prior to the time such increase has been approved by the stockholders of the
Company.

 

(b)       Expiration
Date. Unless earlier terminated as provided herein, the Plan will automatically terminate ten (10) years after the later of
(i) the Effective Date, or (ii) the most recent increase in the Share Reserve that was approved by stockholders; provided, however
that all outstanding Awards shall remain subject to the terms of the Plan and the applicable Award Agreement as in effect immediately
prior to such termination.

    24

     

    

Exhibit
A

 

Schedule
of Shares Reserved for Issuance under the Plan

 

	Date
    of Board	 	Date
    of Stockholder	 	Number
    of	 	Cumulative
    Number
	Approval	 	Approval	 	Shares
    Added	 	of
    Shares
	 	 	 	 	Not Applicable	 	As set forth in 4(a).

 

Summary
of Modifications And Amendments to the plan

 

The
following is a summary of material modifications made to the Plan (including any material deviations from the Bass, Berry &
Sims precedent form used to create the Plan):

 

		1.	Plan
                                         was drafted to include a 10% share reserve float.

		2.	Plan
                                         includes Canadian participant language from Goodmans.

    25Exhibit
10.7

 

POINT
Biopharma Corp.

22
St. Clair Ave. East, Suite 1201,

Toronto,
ON M4T 2S3

 

Allan
Silber

 

POINT
Biopharma Corp. Employment Agreement

 

April
23, 2020

     

     

    

 

 

POINT
Biopharma Corp. Employment Agreement

 

to
be effective as of and from the 

Effective Date (as defined below)

 

PRIVATE
AND CONFIDENTIAL

 

Allan
Silber

106
Old Forest Hill Road

Toronto,
Ontario, Canada

M5P
2R9

 

Dear
Allan:

 

		Re:	Terms
                                         of Employment of Allan Silber (“you” or the “Employee”) with
                                         POINT Biopharma Corp. (the “Company”)

 

This
Agreement (as defined below) sets out the terms and conditions of your employment by the Company and will constitute your employment
agreement.

 

For
and in consideration of the promises herein and other valuable consideration, the parties agree as follows:

 

Article
1 Interpretation

 

		1.1	Definitions

 

For
the purposes of this Agreement:

 

		1.1.1	“$”
                                         means CDN dollars.

 

		1.1.2	“Affiliate”
                                         means with respect to a Person, any Person that, directly or indirectly, Controls, is
                                         Controlled by, or is under common Control with such Person, including, without limitation,
                                         any partner, officer, director, or member of such Person and any venture capital fund
                                         now or hereafter existing that is Controlled by or under common Control with one or more
                                         general partners or shares the same management company or investment manager with such
                                         Person, and including any parent or subsidiary company of such Person.

 

		1.1.3	“Agreement”
                                         means this employment agreement and the exhibits hereto.

 

		1.1.4	“Base
                                         Salary” shall have the meaning set out in Section 3.2 (Base Salary)

 

		1.1.5	“Business”
                                         means the business of the Company described in Exhibit 1.1.5.

    2 

     

    

 

		1.1.6	“Business
                                         Information” means all business information, including information regarding:

 

		.1	commercial
                                         strategies, business plans, business methods, corporate plans, management systems, finances,
                                         new business opportunities, marketing or sales of any past, present or future product
                                         or service, including, without limitation, sales targets and statistics, market share
                                         and pricing statistics, marketing surveys and plans, market research reports, sales techniques,
                                         price lists, discount structures, advertising and promotional material;

 

		.2	financial
                                         information, compensation and investment arrangements, terms of agreements, financial
                                         structure, financial position, financial results or other financial affairs, actual or
                                         proposed transactions or investments or other confidential information; and

 

		.3	the
                                         name, address, telephone number, contact name and identity of each of the Key Contacts,
                                         the nature of their business operation, and all confidential aspects of their business
                                         relationship or potential business relationship with the Company or any Affiliate of
                                         the Company.

 

		1.1.7	“Cause”
                                         shall have the meaning set out in Section 6.6 (Termination by Company for Cause).

 

		1.1.8	“Executive
                                         Chairman” shall have the meaning set out in Section 2.1 (Position and Duties).

 

		1.1.9	“Change
                                         of Control” shall be deemed to have occurred if any of the following occurs
                                         after the Effective Date and before the Termination Date:

 

		.1	any
                                         “person” or “group” (as such terms are defined below) is or becomes
                                         the “beneficial owner” (as defined below, except that a “person”
                                         or “group” shall be deemed to have “beneficial ownership” of
                                         all shares of capital stock or other equity interests if such person or group has the
                                         right to acquire such shares or interests, whether such right is exercisable immediately
                                         or only after the passage of time), directly or indirectly, in a transaction or series
                                         of related transactions, of shares of capital stock or other interests (including partnership
                                         interests) of the Company then outstanding and normally entitled (without regard to the
                                         occurrence of any contingency) to vote in the election of the directors, managers or
                                         similar supervisory positions (“Voting Stock”) of the Company representing
                                         more than fifty percent (50%) of the total voting power of all outstanding classes of
                                         Voting Stock; or;

 

	 	.2	a sale of substantially all of the assets of the Company;
or

 

		.3	the
                                         Company enters into a merger, reverse-merger, amalgamation, arrangement, consolidation
                                         or other form of business combination, share exchange, reorganization, recapitalization,
                                         transfer or other similar transaction with another Person (whether or not the Company
                                         the surviving entity) and as a result of such transaction (a) the members of the board
                                         of directors of the Company immediately prior
to such transaction constitute less than a majority of the members of the board of directors of the Company or such surviving
entity immediately following such transaction or (b) the Persons that beneficially owned, directly or indirectly, the shares of
Voting Stock of the Company immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of
Voting Stock of the Company representing at least a majority of the total voting power of all outstanding classes of Voting Stock
of the surviving entity immediately following such transaction.

    3 

     

    

 

Notwithstanding
the foregoing, a Change of Control resulting from a Financing or from corporate changes between Company Affiliates is deemed not
to be a Change of Control for the purposes of this Agreement.

 

		1.1.10	“Confidential
                                         Information” means all non-public information, knowledge, or data pertaining
                                         to the business, affairs and technology of the Company or any Affiliate of the Company,
                                         including:

 

	 	.1	Technical Information and Business Information;

 

	 	.2	your Work Product; and

 

		.3	information
                                         secured by the Company from Persons subject to an obligation of confidentiality;

 

and,
in all cases, all copies and tangible embodiments thereof, in whatever form or medium, all whether furnished or prepared before
or after the Effective Date.

 

		1.1.11	“Control”
                                         or “Controls” means, in relation to a corporation or a partnership,
                                         as the case may be:

 

		.1	the
                                         right to cast a majority of the votes that may be cast at a general meeting of the shareholders
                                         of a corporation;

 

		.2	the
                                         right to elect or appoint, directly or indirectly, a majority of the directors of a corporation;

 

		.3	to
                                         hold more than 50% of the interests of a partnership other than a limited partnership;
                                         and

 

	 	.4	to be the general partner of a limited partnership.

 

		1.1.12	“Effective
                                         Date” shall have the meaning set out in Section 2.3.4

 

		1.1.13	“Financing”
                                         means capital secured for, and accepted by, the Company including without limitation
                                         through any purchase, transfer or other disposition of any debt, equity or other securities
                                         of the Company.

    4 

     

    

		1.1.14	“Inventions”
                                         means any and all discoveries, developments, enhancements, improvements, concepts, formulas,
                                         processes, ideas, writings, whether or not reduced to practice, industrial and other
                                         designs, patents, patent applications, provisional patent applications, continuations,
                                         continuations-in-part, substitutions, divisionals, reissues, renewals, re-examinations,
                                         extensions, supplementary protection certificates or the like, trade secrets or utility
                                         models, copyrights and other forms of intellectual property including all applications,
                                         registrations and related foreign applications filed and registrations granted thereon.

 

		1.1.15	“Key
                                         Contacts” means the actual and potential: licensors, licensees, sublicensees,
                                         collaborators, partners, investors, shareholders, acquirers, lenders or merger candidates,
                                         suppliers and customers of the Company or any Affiliate of the Company.

 

		1.1.16	“Notice
                                         Period” shall have the meaning set out in Section 6.1 (Termination by Employee)

 

		1.1.17	“Objectives”
                                         shall have the meaning set out in Section 3.3 (Annual Bonus)

 

		1.1.18	“Option
                                         Agreement” shall have the meaning set out in Section 3.4 (Stock Options).

 

		1.1.19	“Person”
                                         means any individual, partnership, joint venture, syndicate, sole proprietorship, company
                                         or corporation with or without share capital, trust, trustee, executor, administrator,
                                         or other legal personal representatives, regulatory body or agency, government or governmental
                                         agency, authority or entity howsoever designated or constituted.

 

		1.1.20	“Technical
                                         Information” means all technical information of the Company or any Affiliate
                                         of the Company, including information regarding knowledge or data of an intellectual,
                                         technical, scientific or industrial nature, including compositions of matter, techniques,
                                         specifications, standards, technical data, uses of matter, practices, methods, computer
                                         data, scientific strategies and concepts, clinical and regulatory strategies and concepts,
                                         test data, research data, analytical and quality control data, formulation data, manufacturing
                                         data, development information, filings for the protection of intellectual property protection,
                                         drawings, specifications, designs, plans, proposals, reports, formulas, compilations,
                                         research data and manuals.

 

		1.1.21	“Term
                                         of Employment” means the period from the Effective Date until the date on which
                                         your employment with the Company ceases in accordance with Article 6.

 

		1.1.22	“Termination
                                         Date” shall have the meaning set out in Section 6.7.

 

		1.1.23	“Work
                                         Product” means any and all works of authorship, including

 

		.1	all
                                         Inventions and possible Inventions relating to the Company’s Business resulting
                                         from any work performed by you for the Company that you may invent or co-invent during
                                         your involvement in any capacity with the Company, except those Inventions invented by
                                         you entirely on your own time that do not relate to the Company’s Business
or do not derive from any equipment, supplies, facilities, Confidential Information or other information, gained, directly or
indirectly, by you from or through your involvement in any capacity with the Company; and

 

		.2	all
                                         Technical Information and Business Information resulting from any work performed by you
                                         for the Company; and includes all analyses, compilations, studies, reports or other documents
                                         prepared by you based upon or including any such information, data or knowledge of the
                                         Company or any Affiliate of the Company.

    5 

     

    

Article
2 Position, Duties and Service

 

2.1          Position
and Duties

 

You
will be employed by and will serve the Company, having the duties and functions customarily performed by, and having all responsibilities
customary to, Executive Chairman, including those described in Exhibit 2.1.

 

You
will report directly to the Board of the Company. The rights of the Company as provided in this Agreement may be exercised on
behalf of the Company only by the Board, or by a committee or person expressly designated for such purposes by the Board.

 

2.2          Changes
to Duties

 

Your
duties and functions pertain to the Company or any Affiliate of the Company and may be varied or added to from time to time by
the Board in its discretion.

 

2.3           Service
to the Company

 

During
the Term of Employment, you will:

 

		2.3.1	well
                                         and faithfully serve the Company, at all times act in the best interests of the Company,
                                         and, to the extent necessary to discharge the responsibilities assigned to you hereunder,
                                         you will use your best efforts to perform faithfully and efficiently such responsibilities;

 

		2.3.2	apply
                                         your skill and experience to the performance of your duties in such employment;

 

		2.3.3	comply
                                         with all policies and procedures from time to time formulated by the Company;

 

		2.3.4	devote
                                         such time, attention and energies as may be required to the business and affairs of the
                                         Company; and

 

		2.3.5	not,
                                         without the prior approval of the Company, carry on or engage in any other business or
                                         occupation or become a director, officer, employee or agent of or hold any position or
                                         office with any other company, firm or person other than the Company, except as disclosed
                                         in Exhibit 2.3.5 or as a volunteer for a non-profit organization, engaging in civic,
                                         religious, educational or other community activities, or
maintaining personal investments or a personal holding company, provided that such activities do not materially interfere with
the performance of your duties under this Agreement.

    6 

     

    

 

2.4           Term

 

The
terms and conditions of this Agreement shall have effect as and from January 6, 2020 (the “Effective Date”)
and throughout the Term of Employment.

 

Article
3 Compensation Generally

 

3.1           No
Other Compensation or Benefits

 

You
will be compensated as set out in this Article. Unless otherwise agreed by the parties in writing, you expressly acknowledge and
agree that you will not be entitled by reason of your employment by the Company or by reason of any termination of such employment,
to any remuneration, compensation, severance, damages or benefits other than as expressly set forth in this Agreement, the Option
Agreement and as expressly required by applicable employment standards legislation.

 

3.2          Base
Salary

 

During
the Term of Employment, the Company will pay you an annual base salary (the “Base Salary”):

 

3.2.1               at
the rate of $275,000 per annum,

 

payable
on a bi-weekly basis (26 pay periods), subject to applicable withholdings and deductions. The Base Salary will be reviewed on
an annual basis, or as otherwise determined by the Company. Any merit increases are subject to the approval and discretion of
the Board. As a managerial employee of the Company, you are not entitled to overtime pay.

 

3.3           Annual
Bonus

 

An
annual bonus will be in effect, and is based on you meeting established performance objectives and due 30 days after the board
has approved the corporate yearend financial statements. During the Term of Employment, you will be eligible for a target
cash bonus of up to 25% of your Base Salary under this Agreement if the Board (or the Company’s Compensation Committee),
in its sole discretion, determines that the Company has met its short-term and long-term business performance objectives and that
you have met your personal performance objectives (together, the “Objectives”), which Objectives will be established
on an annual basis by the Board (or the Company’s Compensation Committee) in consultation with you. Payment of the performance
bonus (less all applicable statutory deductions by the Company) will be made to you once approved by the Board (or Company’s
Compensation Committee), and within 30 days after the board has approved the corporate yearend financial statements, provided
that, except as otherwise set out in this Agreement, at the time of such approval, you hold current active employment status with
the Company. You acknowledge that participation in any incentive or bonus plan during any one year confers no rights upon you
or any obligations on the Company to continue the plan or entitle you to participate in the plan in succeeding years. Except only
as expressly required by the applicable employment standards legislation, as amended, no incentives or bonuses will be paid or
are payable to you following the Termination Date and you waive any entitlement
to damages in lieu thereof whether pursuant or attributable to any common law notice period or otherwise.

    7 

     

    

3.4
          Founders Common Shares

 

You
will receive founders common shares equivalent to 1,000,000 of the initial share capital of the company.

 

3.5          Stock
Options

 

From
time to time, subject to the terms and conditions of the Option Agreement and at the approval of the Board of Directors, you may
be entitled to receive an annual performance-based allocation of stock options in the Company equivalent in shares to 20% of your
salary, i.e. $275,000 X 20% = 55,000 shares.

 

Except
only as expressly required by applicable employment standards legislation, as amended, or expressly required by the terms of this
Agreement, as of the Termination Date, there shall be no further awards of or vesting of stock options, restricted stock units,
or other equity-based compensation, and any unvested stock options, restricted stock units, or other equity-based compensation
shall immediately be cancelled and terminate, and you waive any entitlement to damages in lieu thereof whether pursuant or attributable
to any common law notice period or otherwise.

 

3.6           Stock
Options in the Event of a Change of Control

 

Subject
to the terms and conditions of the Option Agreement, in the event that as of the date of a Change of Control, you hold unvested
stock options that had been granted to you under the Option Agreement, such unvested stock options shall immediately vest and
shall be exercisable in accordance with the terms and conditions of the Option Agreement.

 

3.7           Reimbursement
for Expenses

 

As
of the Effective Date, the Company agrees to reimburse you for reasonable travelling and other expenses incurred in the course
of employment. For all such expenses, you will be required to keep proper accounts and to furnish such statements and vouchers
to the Company.

 

3.8           Vacation

 

During
the Term of Employment, you will be entitled to 20 working days’ vacation, pro-rated for any partial year of employment.
On your five-year anniversary you will be entitled to 25 working days’ vacation. The Company reserves the right to request
that vacations be scheduled so as not to conflict with business needs. While you must take at least your minimum statutory entitlement
to vacation each year, any unused vacation balance remaining at calendar year end in excess of minimum statutory vacation entitlements
may be carried over into the subsequent calendar year to a cumulative maximum not exceeding 40 working days of vacation. Subject
to applicable employment standards legislation, any vacation carried over in excess of 40 days will be forfeited.

    8 

     

    

3.9           Benefits

 

During
the Term of Employment, the Company will provide for group health, drugs, dental, vision and life insurance benefits through a
mutually agreeable arrangement as is made available to its executives from time to time. You hereby acknowledge that coverage
under any benefit plan, or alternate plan arrangement as agreed upon in effect from time to time is subject to availability and
other requirements of the applicable insurer and that the components of the benefits plan may be amended, modified or terminated
from time to time by the Company in its sole discretion, and that this may include terminating or changing carriers.

 

Article
4 Intellectual Property Rights

 

4.1          Obligation
of Confidentiality

 

You
understand and agree that in the course of your employment with the Company, both before and after the Effective Date, you have
obtained and will obtain knowledge of Confidential Information. You agree that unless the Company otherwise agrees in writing
or except as required by law or disclosed pursuant to a confidential disclosure agreement executed by the Company and the recipient:

 

		4.1.1	you
                                         will keep all Confidential Information learned or acquired by you, disclosed to you or
                                         developed by you, as a result of or in connection with or during the course of your employment
                                         by the Company, whether before or after the Effective Date, strictly confidential;

 

		4.1.2	all
                                         Confidential Information shall, as between you and the Company, be and remain the property
                                         of the Company; and

 

		4.1.3	you
                                         will not at any time, during or after your employment with the Company, disclose any
                                         Confidential Information to any Person other than the Company, or use any Confidential
                                         Information for the benefit of any Person other than the Company.

 

The
above obligations with respect to Confidential Information shall not apply to Confidential Information which has become available
to the general public through no fault of your own.

 

4.2           Disclosure
of Work Product

 

You
agree to promptly and fully inform the Company of all of your Work Product, whether or not patentable, throughout the course of
your involvement, in any capacity, with the Company or any Affiliate of the Company, whether or not developed before or after
your execution of this Agreement. On your ceasing to be employed by the Company, you will immediately deliver up to the Company
all of your Work Product. You further agree that all of your Work Product shall at all times be the Confidential Information of
the Company.

 

4.3           Assignment
of Rights

 

You
will assign, and do hereby assign, to the Company or, at the option of the Company and upon notice from the Company, to the Company’s
designee, your entire right, title and interest in and to all of your Work
Product and all other rights and interests of a proprietary nature in and associated with your Work Product, including all patents,
copyrights, trademarks, and applications filed therefore and other registrations granted thereon. To the extent that you retain
or acquire legal title to any such rights and interests, you hereby declare and confirm that such legal title is and will be held
by you only as trustee and agent for the Company. You agree that the Company’s rights hereunder shall attach to all of your
Work Product, notwithstanding that it may be perfected or reduced to specific form after you have terminated your relationship
with the Company. You further agree that the Company’s rights hereunder shall extend to every country of the world.

    9 

     

    

 

4.4           Moral
Rights

 

You
agree to hereby waive in whole all moral rights and agree never to assert any moral rights which you may have in your Work Product,
including, without limitation, the right to the integrity of such Work Product, the right to be associated with the Work Product,
the right to restrain or claim damages for any distortion, mutilation or other modification or enhancement of the Work Product
and the right to restrain, the use or reproduction of the Work Product in any context and in connection with any product, service,
cause or institution and you further confirm that the Company may use or alter any such Work Product as the Company sees fit in
its absolute discretion.

 

4.5           Goodwill

 

You
hereby agree that all goodwill you have established or may establish with Key Contacts relating to the business or affairs of
the Company or any Affiliate of the Company, both before and after the Effective Date, shall, as between you and the Company,
be and remain the property of the Company exclusively, for the Company to use, alter, vary, adapt and exploit as the Company shall
determine in its discretion.

 

4.6           Assistance

 

You
hereby agree to assist the Company, at the Company’s request and expense, both during your Term of Employment and as you
can after termination of your Term of Employment for any reason whatsoever, in:

 

		4.6.1	making
                                         patent applications for your Work Product, including instructions to lawyers and/or patent
                                         agents as to the characteristics of your Work Product in sufficient detail to enable
                                         the preparation of a suitable patent specification, to execute all formal documentation
                                         incidental to an application for letters patent and to execute assignment documents in
                                         favor of the Company for such applications;

 

		4.6.2	making
                                         applications for all other forms of intellectual property registration relating to your
                                         Work Product;

 

		4.6.3	prosecuting
                                         and maintaining the patent applications and other intellectual property relating to your
                                         Work Product; and

 

		4.6.4	registering,
                                         maintaining and enforcing the patents and other intellectual property registrations relating
                                         to your Work Product.

    10 

     

    

4.7           Assistance
with Proceedings

 

You
further agree to lend such assistance as you can, at the Company’s request and expense, in connection with any enforcement
of the Company’s intellectual property rights or defense to an allegation of infringement of another Person’s intellectual
property rights, invalidity proceedings respecting, opposition to, or intervention regarding any applications for letters patent,
copyright or trademark or other proceedings relating to intellectual property or applications for registration thereof.

 

Article
5 Conflicts and Restrictive Covenant

 

5.1           Disclosure
of Conflicts of Interest

 

During
your employment with the Company, you will promptly, fully and frankly disclose to the Company in writing:

 

		5.1.1	the
                                         nature and extent of any interest you have or may have, directly or indirectly, in any
                                         contract or transaction or proposed contract or transaction of or with the Company or
                                         any Affiliate of the Company or any Key Contact;

 

		5.1.2	every
                                         office you may hold or acquire, and every property you may possess or acquire, whereby
                                         directly or indirectly, a duty or interest might be created in conflict with the interests
                                         of the Company or any Affiliate of the Company, or your duties and obligations under
                                         this Agreement; and

 

		5.1.3	the
                                         nature and extent of any conflict referred to in Sections 5.1.1 and 5.1.2.

 

		5.2	Avoidance
                                         of Conflicts of Interest 

 

You
acknowledge that it is the policy of the Company that all interests and conflicts of the sort described in Section 5.1 (Disclosure
of Conflicts of Interest) be avoided, and you agree to comply with all policies and directives of the Company from time to time
regulating, restricting or prohibiting circumstances giving rise to interests or conflicts of the sort described in Section 5.1.
During your employment with the Company, you shall not enter into any agreement, arrangement or understanding with any other Person
that would in any way conflict or interfere with this Agreement or your duties or obligations under this Agreement or that would
otherwise prevent you from performing your obligations hereunder, and you represent and warrant that you have not prior to the
Effective Date entered into any such agreement, arrangement or understanding.

 

5.3           Restrictive
Covenant

 

During
the Term of Employment and for a period of 6 months thereafter for Sections 5.3.1 and 5.3.2, and a period of 18 months thereafter
for Section 5.3.3, regardless of the reason for such termination, you will not, either alone or in partnership or in conjunction
with any Person, whether as principal, agent, employee, director, officer, shareholder, consultant or in any capacity or manner
whatsoever, whether directly or indirectly:

    11 

     

    

		5.3.1	carry
                                         on or be engaged in, or advise, or give financial assistance to, any business, enterprise
                                         or undertaking within Canada that:

 

		.1	is
                                         involved in the business or in the sale, distribution, development or supply of any product
                                         or service that is competitive with the Business or any product or service of the Business;
                                         or

 

		.2	competes
                                         with the Company with respect to any aspect of the Business; provided, however, that
                                         the foregoing will not prohibit you from acquiring, solely as an investment and through
                                         market purchases, securities of any such enterprise or undertaking which are publicly
                                         traded, so long as you are not part of any control group of such entity and such securities,
                                         which if converted, do not constitute more than 5% of the outstanding voting power of
                                         that entity;

 

		5.3.2	agree
                                         to be employed by, or agree to provide services within Canada to any Person that was
                                         a Key Contact (but in any case, with whom you have had business contact during the two
                                         years prior to the termination of the Term of Employment, or with whom you have had business
                                         contact in the course of your employment with the Company if less than 24 months) for
                                         any business purpose that is competitive with the Business; or

 

		5.3.3	solicit,
                                         divert, entice or take away from the Company or any Affiliate of the Company or attempt
                                         to do so or solicit for the purpose of doing so, any business of the Company or any Affiliate
                                         of the Company, or any Person that was an employee or contractor of the Company or any
                                         Affiliate of the Company (but in any case, with whom you have had business contact during
                                         the 18 months prior to the termination of the Term of Employment, or with whom you have
                                         had business contact in the course of your employment with the Company if less than 18
                                         months) to terminate, discontinue or alter to the detriment of the Company, his, her
                                         or its employment relationship with the Company or its Affiliates.

 

		5.4	Provisions
                                         Reasonable 

 

You
hereby acknowledge and agree that:

 

		5.4.1	during
                                         the course of your employment by the Company, you will acquire knowledge of, and you
                                         will come into contact with, initiate and established relationships with Key Contacts,
                                         and that in some circumstances you may be the senior or sole representative of the Company
                                         or any Affiliate of the Company dealing with such Persons; and

 

		5.4.2	in
                                         light of the foregoing, the provisions of Section 5.3 (Restrictive Covenant) are reasonable
                                         and necessary for the proper protection of the business, property and goodwill of the
                                         Company and the Business and any Affiliate of the Company.

    12 

     

    

		5.5	Right
                                         to Use Employee’s Name and Likeness 

 

During
the Term of Employment, you hereby grant to the Company the right to use your name, likeness and/or biography in connection with
services performed by you under this Agreement and in connection with the advertising or exploitation of any project with respect
to which you perform services for the Company.

 

Article
6 Termination

 

6.1           Termination
by Employee

 

You
may resign from your position at any time, but only by giving the Company at least 30 days prior written notice of the effective
date of your resignation (the “ Notice Period “). On the giving of any such notice, the Company may accelerate
your resignation, in lieu of the Notice Period or any part thereof, by notice in writing to you and payment to you of any compensation
and continuation of benefits due to you for the balance of the 30-day Notice Period pursuant to this Agreement, less applicable
statutory deductions.

 

6.2           Termination
by Company Without Cause

 

The
Company may terminate your employment at any time without Cause (as defined below) in accordance with the terms set out in this
Agreement and by giving you written notification of termination. In the event that your employment is so terminated, you will
have the common law duty to mitigate your damages.

 

6.3           Consequences
of Termination Without Cause Unrelated to a Change of Control

 

Subject
to Section 6.4, on the giving of any notice referred to in Section 6.2, the Company shall provide you with the greater of either
(i) 3 months’ Base Salary and bonus (3.3), in addition to 1 month for every year of service (or part thereof) to the company
upon and effective at 3 years of employment, , or (ii) the minimum notice or pay in lieu of notice and severance pay, if applicable,
that is expressly required by applicable employment standards legislation. In the case of either Section 6.3(i) or (ii), your
participation in Company benefits plans will be continued for the minimum period expressly required by applicable employment standards
legislation. Other than as set out in this Section and Section 6.7, you will not be entitled to any additional notice, pay in
lieu of notice, severance or other payments whether pursuant to the common law or otherwise upon termination of your employment
without Cause unrelated to a Change of Control pursuant to this Section 6.3.

 

6.4          Consequences
of Termination Without Cause After a Change of Control

 

On
the giving by the Company to you of the written notice referred to in Section 6.2: (i) at the same time as, or within the twelve
(12) month period following, the consummation of a Change of Control, or (ii) within the thirty (30) day period prior to the date
of the consummation of a Change of Control where such Change of Control was under consideration by the Board at the time of your
termination, then the following terms apply in substitution of the compensation and benefits referred to in Section 6.3 above:

 

		6.4.1	the
                                         Company shall provide you with the greater of either (i) 6 months’ Base Salary
                                         and bonus (3.3), in addition to 1 month for every year of service (or part thereof) to
                                         the company, upon and effective at 3 years of employment. , or (ii) the minimum notice
                                         or pay in lieu of notice and severance pay, if applicable, that is expressly required
by applicable employment standards legislation, plus in the case of either Section 6.4.1(i) or (ii), your participation in Company
benefits plans will be continued for the minimum period expressly required by applicable employment standards legislation; and

    13 

     

    

		6.4.2	as
                                         set out in and subject to the terms of Section 3.5 above, as of the date of the consummation
                                         of the Change of Control, any unvested stock options granted to you under the Option
                                         Agreement will vest and be exercisable in accordance with the terms and conditions of
                                         this Option Agreement.

 

Other
than as set out in this Section and Section 6.7 below, you will not be entitled to any additional vesting, notice, pay in lieu
of notice, severance or other payments whether pursuant to the common law or otherwise upon termination of your employment without
Cause after a Change of Control pursuant to this Section 6.4.

 

6.5          Termination
in the Event of Death

 

Your
employment shall terminate immediately upon your death and the Company shall pay your estate any amounts which may be due and
remaining unpaid at the time of the termination of employment, in accordance with applicable employment standards legislation.

 

6.6
           Termination by Company for Cause

 

Notwithstanding
any other provision in this Agreement, the Company may at any time summarily terminate your employment, without any obligation
to provide notice of pay in lieu of notice, for “Cause”, in which case you will only be entitled to receive such compensation
and benefits as are expressly required by applicable employment standards legislation. In this Agreement, “Cause”
means any of the following:

 

		6.6.1	commission
                                         of theft, embezzlement, fraud, obtaining funds or property under false pretenses or similar
                                         acts of misconduct with respect to the property of the Company, any Affiliate of the
                                         Company, the Key Contacts, or their respective directors, officers, employees or contractors;

 

oral
or written representations made by you to the Company or any Affiliate of the Company with the intent to deceive or mislead; commission
of an act of malfeasance, dishonesty or breach of trust against the Company, any Affiliate of the Company, the Key Contacts, or
their respective directors, officers, employees or contractors, including a breach by you of any of your covenants or obligations
under Section 5.1 (Disclosure of Conflicts of Interest), Section 5.2 (Avoidance of Conflicts of Interest) or Section 5.3 (Restrictive
Covenant);

 

		6.6.2	the
                                         entering of a guilty plea by you or your conviction for a serious criminal offence which
                                         impacts adversely on the Company or any Affiliate of the Company;

 

		6.6.3	repeated
                                         and continued failure to fulfill your duties or obligations of employment or your breach
                                         of any material obligations and covenants under this Agreement. Termination for such
                                         “Cause” shall only occur if you have been given written notice of
such failure to fulfill your duties or obligations and you have been given an opportunity to correct such behavior;

    14 

     

    

		6.6.4	the
                                         termination of your employment with POINT Biopharma Corp. other than a termination pursuant
                                         to section 6.2 ; or

 

		6.6.5	any
                                         other misconduct or omission that amounts to just cause for summary dismissal at common
                                         law. In the event the Company dismisses you for cause pursuant to this Section 6.6 and,
                                         subsequently, a court or arbitrator rules that the Company did not have cause, you hereby
                                         agree that you will only be entitled to damages in an amount equal to the compensation
                                         that would have been due to you had the Company terminated your employment pursuant to
                                         Section 6.3 (Consequences of Termination Without Cause), less any amounts earned by you
                                         in mitigation.

 

		6.7	Termination
                                         Date and Full Satisfaction 

 

“Termination
Date” means the earlier of: (i) the date on which you are notified in writing by the Company of the termination of your
employment for any reason, and (ii) the date on which you notify the Company of your resignation from employment for any reason,
but in any case, without regard to any payment or notice period to which you might then be entitled.

 

It
is agreed that as a result of the termination of your employment, for any reason, you shall not be entitled to any notice, fee,
salary, severance or other payments, benefits or damages in excess of what is specified or provided for in Section 6.1 (Termination
by Employee), Section 6.3 (Consequences of Termination Without Cause Unrelated to a Change of Control), Section 6.4 (Consequences
of Termination Without Cause After a Change of Control) and Section 6.6 (Termination by Company for Cause), whichever is applicable,
except that you shall remain receive all salary and other amounts, if any, which are then due and owed to you as of the Termination
Date, in addition to any accrued but unpaid vacation pay and any other minimum entitlements expressly required to be provided
to you by applicable employment standards legislation. Payment of any amounts pursuant to Section 6.1 (Termination by Employee),
Section 6.3 (Consequences of Termination Without Cause Unrelated to a Change of Control), Section 6.4 (Consequences of Termination
Without Cause After a Change of Control), and Section 6.6 (Termination by Company for Cause) shall be subject to the withholding
of all applicable statutory deductions by the Company. You will be required to execute a standard release of claims document in
a form satisfactory to the Company in order to receive any payments in excess of those required by applicable employment standards
legislation.

    15 

     

    

Article
7 General

 

7.1           Agreement
Confidential

 

Both
parties shall keep the terms and conditions of this Agreement confidential except as may be required to enforce any provision
of this Agreement or as may otherwise be required by any law, regulation or other regulatory or securities requirement.

 

7.2          Binding
Effect

 

This
Agreement shall be binding upon and inure to the benefit of the Company and its successors and assigns. Your rights and obligations
contained in this Agreement are personal and such rights, benefits and obligations shall not be voluntarily or involuntarily assigned,
alienated or transferred, whether by operation of law or otherwise, without the prior written consent of the Company. This Agreement
shall otherwise be binding upon and inure to the benefit of your personal or legal representatives, executors, administrators,
successors, heirs, distributees, devisees, legatees and permitted assigns.

 

7.3           Counterparts

 

This
Agreement may be executed in several counterparts (including by fax or electronic transmission), each of which when so executed
shall be deemed to be an original and shall have the same force and effect as an original but such counterparts together shall
constitute but one and the same instrument.

 

7.4           Entire
Agreement

 

The
terms and conditions of this Agreement are in addition to and not in substitution for the obligations, duties and responsibilities
imposed by law on employees of corporations generally, and you agree to comply with such obligations, duties and responsibilities.
Except as otherwise provided in this Agreement, this Agreement constitutes the entire agreement between you and the Company and
supersedes all prior negotiations, proposals and agreements, whether oral or written, with respect to the subject matter hereof,
and may only be varied by further written agreement signed by you and the Company. You further acknowledge and agree that you
have not relied on any representation made by the Company, or any of its employees or agents, except as specifically set out in
this Agreement.

 

7.5           Further
Assurances

 

Each
of the parties hereto will, on demand by the other party hereto, execute and deliver all such further documents and instruments
and do all such further acts and things as the party may either before or after the execution and delivery of this Agreement reasonably
request to evidence, carry out and give full effect to the terms, conditions, intent and meaning of this Agreement.

 

7.6           Governing
Law

 

This
Agreement shall be construed and enforced in accordance with and be governed by and interpreted in accordance with the laws of
the Province of Ontario and the law of Canada applicable therein, without regard to the principles of conflicts of law. The courts
of Ontario (and the Supreme Court of Canada, if necessary) shall have exclusive jurisdiction to hear and determine all disputes
arising hereunder, and each of the parties hereto irrevocably attorns to the jurisdiction of said courts.

    16 

     

    

7.7           Independent
Legal Advice

 

You
acknowledge and agree that the Company has given you the opportunity to seek, and has recommended that you obtain, independent
legal advice with respect to the subject matter of this Agreement and, further, you hereby represent and warrant to the Company
that you have either sought independent legal advice or have waived your right to obtain such advice.

 

7.8           Injunctive
Relief

 

You
acknowledge and agree that any breach or threatened breach of any of the provisions of, Section 5.1 (Disclosure of Conflicts of
Interest), Section 5.2 (Avoidance of Conflicts of Interest), or Section 5.3 (Restrictive Covenant) could cause irreparable damage
to the Company, that such harm could not be adequately compensated by the Company’s recovery of monetary damages, and that
in the event of a breach or threatened breach thereof, the Company shall have, in addition to any and all remedies at law or in
equity, the right to seek an injunction, specific performance or other equitable relief as well as any equitable accounting of
all your profits or benefits arising out of any such breach. It is further acknowledged and agreed that the remedies of the Company
specified in this Section 7.8 are in addition to and not in substitution for any rights or remedies of the Company at law or in
equity and that all such rights and remedies are cumulative and not alternative and that the Company may have recourse to any
one or more of its available rights or remedies as it shall see fit.

 

7.9           Non-Disparagement

 

You
shall not, directly or indirectly, make any disparaging comments or criticisms (whether of a professional or personal nature)
to any Person regarding the Company, any Affiliate of the Company, the Key Contacts, or their respective directors, officers,
employees or contractors (or the terms of any agreement or arrangement of the Company) or regarding your relationship with the
Company or any termination of such relationship which, in each case, are reasonably expected to result in material damage to the
business or reputation of the Company, any Affiliate of the Company, a Key Contact, or any of their respective directors, officers,
employees or contractors.

 

7.10        Notice

 

Any
notice or other communication required or contemplated to be given hereunder must be in writing and shall be deemed effective
when personally delivered or on the day following the sending when sent by facsimile transmission, addressed to the appropriate
party as set forth below:

 

If
to the Employee:

 

Allan
Silber

106
Old Forest Hill Road

Toronto,
Ontario, Canada

M5P
2R9

    17 

     

    

 

If
to the Company:

 

POINT
Biopharma Corp.

22
St. Clair Ave. East, Suite 1201,

Toronto,
ON M4T 2S3

 

Attention:
CEO, Joe McCann

 

With
a copy to (which shall not constitute notice):

 

Goodmans
LLP

Bay
Adelaide Centre - West Tower

333
Bay Street, Suite 3400

Toronto,
ON

M5H
2S7

 

7.11        Publicity

 

You
shall not, without the prior written consent of the Company, make or give any public announcements, press releases or statements
to the public or the press regarding your Work Product or any Confidential Information.

 

7.12        Severability

 

If
any provision of this Agreement is determined to be void, illegal or unenforceable, such provision will be construed to be separate
and severable from this Agreement and will not impair the validity, legality or enforceability of any other provision of this
Agreement and the remainder of this Agreement will continue to be binding on the parties hereto as if such provision had been
deleted.

 

7.13        Surviving
Obligations

 

Upon
termination of this Agreement for any reason, any obligations which by their terms or nature, must extend beyond the date of termination
to be effective shall survive termination of this Agreement. Without limiting the foregoing, your obligations under Section 5.3
(Restrictive Covenant), Section 5.4 (Provisions Reasonable), Article 6 (Termination) and Article 7 (General) shall survive and
remain in full force and effect following the termination of this Agreement.

 

7.14        Waiver

 

Any
waiver of any breach or default under this Agreement shall only be effective if made in writing, signed by the party against whom
the waiver is sought to be enforced, and no waiver shall be implied by any other act or conduct or by any indulgence, delay or
omission. Any waiver shall only apply to the specific matter waived and only in the specific instance in which it is waived.

    18 

     

    

7.15       Acceptance

 

If
the foregoing terms and conditions are, are acceptable to you, please indicate your acceptance of and agreement to the
terms and conditions of this agreement by singing below on this letter and on the enclosed copy of this letter in the
space provided and by returning the enclosed copy so executed to us. Your execution and delivery to to Company of the
enclosed copy of this letter will create a binding agreement between us .

 

Yours
truly,

Point
Biopharma Corp.

 

Per:
/s/ Joe McCann

Authorized
Signatory

 

Joe
McCann, Chief Executive Officer

 

Acknowledged
and Agreed:

 

I
acknowledge that I have had sufficient time to thoroughly review this agreement and obtain the advice that I deem appropriate
regarding its terms and conditions. I have read, understand and voluntarily accept employment with POINT Biopharma Corp. on the
terms and conditions set out above.

 

	April 23,
    2020	/s/Allan
    Silber 	 
	Date 	Allan
    Silber	 

    19 

     

    

 

Exhibit
1.1.5: Description of the Business

 

The
Company is a clinical stage pharmaceutical company focused on the development and commercialization of radiotherapeutics and theranostic
products. The company will compete in all medical therapeutic categories.

    20 

     

    

Exhibit
2.1: Description of Duties –Executive Chairman

 

The
Executive Chairman reports directly to the Board and works with CEO in making strategic decisions to achieve the companies
stated business and financial objectives.

 

ESSENTIAL
DUTIES AND RESPONSIBILITIES

 

		•	Work
                                         with the board, CEO, senior stakeholders and leadership team to develop the corporate
                                         objectives to achieve the company’s goals;

		•	Provide
                                         overall leadership to enhance the effectiveness and performance of the Board and act
                                         as the primary spokesperson for the Board;

		•	In
                                         conjunction with the CEO, lead POINT in its relationships with shareholders and financial
                                         institutions;

		•	Lead
                                         financing strategy and implementation in consultation with the Chief Executive Officer
                                         and Board;

		•	Lead
                                         transactional strategy and implementation in consultation with the Chief Executive Officer
                                         and Board;

		•	Working
                                         with the CEO, develop POINT’s corporate strategy, build a pipeline of potential
                                         merger and acquisition transactions, grow POINT’s market profile and establishing
                                         new corporate relationships;

		•	Working
                                         with the CEO, negotiate key financing transaction, merger and acquisition transactions,
                                         in- and out-licensing deals and key contracts;

		•	With
                                         the Board of Directors and the CEO, support the creation the company’s vision and
                                         mission and short- and long-term objective and strategies;

		•	Act
                                         as an adviser and confidant to the Chief Executive Officer;

		•	Foster
                                         ethical and responsible decision making by the Board, Board Committees and the individual
                                         Directors;

		•	Maintain
                                         an awareness of the competitive market landscape, expansion opportunities and industry
                                         developments;

		•	Ensuring
                                         that the company maintains high social responsibility wherever it does business;

		•	Assess
                                         risks to the company and ensures they are monitored and minimized;

		•	Build
                                         alliances and partnerships with other organizations, key partners and stakeholders and
                                         act as a point of contact for important partners;

		•	Oversee
                                         day-to-day operation of the company, and;

		•	Represent
                                         the company as required, including attendance of important functions, industry events
                                         and public meetings.

 

BOARD
COMMITTEES

		•	Assist
                                         in recommending appointees to Board Committees and in reviewing the need for, and the
                                         performance and suitability of, those committees;

		•	Ensure
                                         the duties and responsibilities of the Board Committees are carried out in accordance
                                         with the Board Committee charters; and

    21 

     

    

 

		•	Assist
                                         the Board Committees in bringing their recommendations forward to the Board for consideration.

 

BOARD
MEETING

 

		•	Ensure
                                         the Board meets at least four times a year and otherwise as required;

		•	Prepare
                                         the agenda for all meetings of the Board in consultation with the Chief Executive Officer
                                         and the Corporate Secretary;

		•	Ensure
                                         that all matters required to be considered by the Board are brought to a meeting of the
                                         Board in a timely fashion;

		•	Monitor
                                         the adequacy of materials provided to the Board by management in connection with the
                                         Board deliberations, and ensure that members of the Board have sufficient time to review
                                         the materials provided to them and to fully discuss the business that comes before the
                                         Board during deliberations;

		•	Ensure
                                         that all items set out in the agenda are properly discussed, considered and resolved;

		•	Ensure
                                         sufficient time is provided to discuss agenda items;

		•	Create
                                         a cooperative atmosphere where Board members are encouraged to openly discuss, debate
                                         and question matters requiring Board attention in a constructive and productive fashion;
                                         and

		•	Ensure
                                         that the independent members of the Board meet in separate in camera sessions at each
                                         Board meeting.

 

SHAREHOLDER
MEETINGS

 

		•	Ensure
                                         the shareholders meet at least once a year and otherwise as required by applicable law;

		•	Ensure
                                         that all items set out in the notice of meeting are properly discussed, considered and
                                         resolved

    22 

     

    

Exhibit
2.3.5: Permitted External Roles

 

		1.	Heritage
                                         Global Capital Inc., Chairman

		2.	Verity
                                         Pharmaceuticals Inc., Chairman

    23 

     

    

	OFFICE
                                         833.544.2637
 FAX
                                         647.243.8490

         

        22
        St. Clair         Avenue East, Suite 1201
         Toronto, Ontario, M4T 2S3, Canada

         

        4850
W 78th St Indianapolis, Indiana, 46268, USA 
	 

 

March
8, 2021

 

Allan
Silber 

106
Old Forest Hill Road 

Toronto,
ON M5P 2R9

 

Dear
Allan,

 

In
connection with the Employment Agreement (the “Employment Agreement”) dated April 23, 2020 between you and
Point Biopharma Corp. (the “Company”), you agree that the provisions set out in this letter agreement amend
the Employment Agreement.

 

Signing
Bonus

 

You
have agreed with the Company to accept a signing bonus of $2,000.00, which will be paid to you by the Company in consideration
for your agreement to the amendments to the Employment Agreement set out in this letter agreement as evidenced by your signed
Acceptance below.

 

Definitions

 

The
definitions of “Affiliate” and “Key Contacts” in Sections 1.1.2 and 1.1.15 of the Employment Agreement
are deleted and replaced with the following:

 

1.1.2
          “Affiliate” means with respect to a Person, any Person
that, directly or indirectly, Controls, is Controlled by, or is under common Control with such Person, including, without limitation,
any partner, officer, director, or member of such Person and any venture capital fund now or hereafter existing that is Controlled
by or under common Control with one or more general partners or shares the same management company or investment manager with
such Person, and including any parent or subsidiary company of such Person and “Protected Affiliate” means
an Affiliate with whom you have been actively engaged in business contact in the course of your employment with the Company in
the 18 months prior to the Termination Date (as that term is defined in subsection 5.3.3.1 of this Agreement) or in respect of
whom you acquired confidential or proprietary information during the course of your employment with the Company that the Company
has a reasonable and legitimate business interest in protecting from use or disclosure by its former employees.

 

1.1.15
“Key Contacts” means the actual and potential licensors, licensees, sublicensees, collaborators, partners,
investors, shareholders, acquirers, lenders or merger candidates, suppliers and customers of the Company or any Protected Affiliate
with whom you have been actively engaged in business contact or actively engaged in researching, developing or preparing a business
pitch or proposal in the course of your employment with the Company in the 18 months prior to the Termination Date, or in respect
of whom you acquired confidential or proprietary information during the course of your employment with the Company that the Company
has a reasonable and legitimate business interest in protecting from use or disclosure by its former employees.

     

     

    
	OFFICE
                                         833.544.2637
 FAX
                                         647.243.8490

         

        22
        St. Clair         Avenue East, Suite 1201
         Toronto, Ontario, M4T 2S3, Canada

         

        4850
W 78th St Indianapolis, Indiana, 46268, USA 
	 

 

Restrictive
Covenant

 

Sections
5.3 and 5.4 of the Employment Agreement are deleted and replaced with the following:

 

5.3           Restrictive
Covenants

 

During
the Term of Employment and for a period of 6 months thereafter for Sections 5.3.1 and 5.3.2, and a period of 18 months thereafter
for Section 5.3.3, regardless of the reason for such termination, you will not, either alone or in partnership
or in conjunction with any Person, whether as principal, agent, employee, director, officer, shareholder, consultant or in any
capacity or manner whatsoever, whether directly or indirectly:

 

5.3.1        carry on or be engaged in, or advise, or give financial assistance to, any business, enterprise or undertaking within Canada and
the United States that:

 

.1             is involved in the business or in the sale, distribution, development or supply of any product or service that is the same as
or substantially similar to the products or services offered by the Company as at the date of the termination of your employment
(the “Termination Date”); or

 

.2             competes in a substantial or material way with the Company with respect to any aspect of the Business as at the Termination Date;
provided, however, that the foregoing will not prohibit you from acquiring, solely as an investment and through market purchases,
securities of any such enterprise or undertaking which are publicly traded, so long as you are not part of any control group of
such entity and such securities, which if converted, do not constitute more than 5% of the outstanding voting power of that entity;

 

5.3.2
        agree to be employed by any Person that was a Key Contact as at the Termination Date for any business purpose that is competitive
with the Business in any substantial or material way; or make use of any list or proprietary information of or relating to a Key
Contact for the purpose of competing with the Company; or be involved in the sale to, solicitation of or servicing of any Key
Contact where such sale, solicitation or servicing is with respect to services or products which are the same or substantially
similar to or which compete with products or services sold or provided by the Company as at the Termination Date; or otherwise
attempt to interfere with or damage the Company’s business relationship with any Key Contact; or

 

5.3.3
        solicit, divert, entice, persu or take away from the Company or any Protected Affiliate the Company has a reasonable need to protect
against (a “Protected Affiliate”), or attempt to do so or solicit for the purpose of doing so, any business of the
Company or any Protected Affiliate, or any Person that was an employee or contractor of the Company or any Protected Affiliate
(but in any case, with whom you have had business contact in the course of your employment with the Company during the 18 months
prior to the Termination Date) to terminate, discontinue or alter to the detriment of the Company, his, her or its employment
or engagement relationship with the Company or its Protected Affiliates or otherwise attempt to interfere with or damage the Company’s
or a Protected Affiliate’s relationship with any such person.

 

		5.4	Provisions
                                         Reasonable

 

You
hereby acknowledge and agree that:

 

5.4.1
        the Company has a material interest in preserving the relationships it has developed with its Key Contacts against impairment
by competitive activities of a former employee;

 

5.4.2
        during the course of your employment by the Company, you will acquire knowledge of, and you will come into contact with, initiate
and establish relationships with Key Contacts, and that in some circumstances you may be the senior or sole representative of
the Company or any Protected dealing with such Key Contacts; and

 

5.4.3
         in light of the foregoing, the provisions of Section 5.3 (Restrictive Covenant) are reasonable and necessary for the proper protection
of the business, property and goodwill of the Company and the Business and any Protected Affiliate and you further agree that
these restrictions and your agreement to them are of major importance to the Company, which would not employ or continue to employ
you if you did not agree to them.

     

     

    

	OFFICE
                                         833.544.2637
 FAX
                                         647.243.8490

         

        22
        St. Clair         Avenue East, Suite 1201
         Toronto, Ontario, M4T 2S3, Canada

         

        4850
W 78th St Indianapolis, Indiana, 46268, USA 
	 

 

Non-Disparagement

 

Section
7.9 of the Employment Agreement is deleted and replaced with the following:

 

You
shall not, directly or indirectly, make any disparaging comments or criticisms (whether of a professional or personal nature and
including any comments, statements or postings via any social media website or application, including but not limited to Facebook,
Twitter, LinkedIn, Flickr, YouTube, Picase, Snapchat, Instagram, TikTok or Clubhouse) to any Person regarding the Company, any
Affiliate of the Company, the Key Contacts, or their respective directors, officers, employees or contractors (or the terms of
any agreement or arrangement of the Company) or regarding your relationship with the Company or any termination of such relationship
which, in each case, are reasonably expected to result in material damage to the business or reputation of the Company, any Affiliate
of the Company, a Key Contact, or any of their respective directors, officers, employees or contractors.

 

No
Other Amendments

 

The
parties acknowledge and agree that, except as specifically amended above in this letter agreement, the Employment Agreement (including
all definitions therein) remains in full force and effect, unamended. All capitalized terms in this letter agreement which are
not otherwise defined shall have the same meaning as in the Employment Agreement. 

 

	/s/
    Joe McCann	 
	For and on behalf of Point Biopharma Corp.	 

 

Acceptance

 

I
have read and understand the terms and conditions of employment set out in the Employment Agreement , as amended by this letter
agreement and I agree to and accept them freely and voluntarily. I confirm that I have had the opportunity to obtain advice regarding
its contents, including from counsel of my choice. I understand that, in the event of the termination of my employment (including
without just cause), my entitlements will be limited to those specified in this agreement.

 

Signed
in Toronto, Ontario on March Don, 2021.

 

	     /s/ Donna Husack	 	/s/ Allan
    Silber
	Witness Signature	 	Allan Silber
	 	 	 	 
	Name:	Donna Husack

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]